[{"article": "Most head and neck cancers are linked to alcohol consumption and to smoking.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nThat's probably not what University of Milan researchers Carlotta Galeone, ScD, PhD, and colleagues thought they'd find when they analyzed nine studies comparing 5,139 people with head and neck cancer to 9,028 people without cancer.\nBut whether these substances actually protect against cancer in humans is a question for future studies.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable \u2013 there really wasn\u2019t any background given on the types of cancer in question. ", "answer": 2}, {"article": "UCH-L1 is released by brain nerves when they\u2019re stressed, and its levels rise more rapidly immediately after injury and peak at eight hours.\nBut there aren\u2019t good ways to distinguish between mild blows that don\u2019t require additional care and mild to moderate traumatic brain injury (TBI), which could have more serious consequences.\nAnd because levels of GFAP tend to remain higher for many days, Papa says it might be useful in cases where patients don\u2019t come in immediately after a head injury, thinking they\u2019re okay, but see the doctor several days later because they\u2019re concerned.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\nMORE: A New Blood Test to Diagnose Concussions On The Field\n\nIn the emergency room, a blood test for UCH-L1 could also help doctors decide which patients should get a CT scan \u2014 the higher their levels of the protein are, the more likely they are to have TBI and would benefit from a scan, while those with lower levels probably don\u2019t need one.\n", "question": "Does the story commit disease-mongering?", "explanation": "No obvious disease mongering in this story. Concussions and traumatic brain injury are a serious public health issue.", "answer": 1}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\nFindings of the clinical trial are published today in the journal, Cardiovascular Diabetology.\nExperts found that the stem cells of patients who took metformin were able to promote the repair of the blood vessels and there was an improvement in how vascular stem cells worked.\nResearchers studied a treatment group of 23 people aged 19-64 who had Type 1 diabetes for up to 23 years and had no evidence of heart disease.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not appear to commit disease mongering.", "answer": 1}, {"article": ".\nThis study expands on the researchers' previous finding that dTMS reduced food cravings and induced weight loss in obese individuals.\nHe and his co-workers studied whether dTMS could improve the gut microbiota composition in obese persons and, if so, by what underlying mechanisms.\nLuzi said scientists now know that an impaired gut microbiota can alter the brain's signals for appetite and satiety, or fullness.\n\"Our research shows the innovative ability of dTMS in exerting anti-obesity effects through alteration of the gut-brain axis.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. Obesity is an increasing problem on both the individual and population-level scales. The release provides some context about why new obesity treatments are needed, as well as the possible role gut microbes might play in weight management.", "answer": 1}, {"article": "\"I know that I can just sort of be on my sits bones, instead of a funny arch with my stomach pushed out or my back arched in some strange way,\" says Rodriguez\n\nJosephine Gray is Rodriguez's teacher and is a certified instructor in Alexander Technique.\nBut there is evidence it can ease chronic low back pain over the long run.\nBut finding a remedy for back pain can be a lot like a guessing game.\nAfter a year, those who had massage were no better off.\nThose who had six Alexander lessons showed some improvement.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no significant disease mongering in this article. Chronic low back pain is a common problem for which there are limited effective treatments.\u00a0\n", "answer": 1}, {"article": "We need to assess these options before jumping to possible universal screening.\"\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nAmong the 5,798 children who would not have been screened, nearly 10% had elevated LDL cholesterol levels (above 130 mg/dL), according to the study, published in the August issue of Pediatrics.\nThat allowed Neal and his team to determine how many children who actually had high cholesterol would have been missed if they had been screened based on federal guidelines.\nIndeed, of all the children in the study whose LDL levels were above 160, one-third were in the group who would not have been screened.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe lead of the story focuses on the number of children with elevated cholesterol who might be missed based on current national guidelines and does not jump to the conclusion that these children would necessarily benefit from treatment. The story also reports that less than two percent of the children tested had cholesterol levels high enough that doctors might consider drug treatment. Oddly, the lead sentence says current guidelines \u201cmay miss nearly 10% of those who have high levels of LDL, or bad cholesterol,\u201d but the researchers put the figure at closer to a third. It may be that the reporter confused the proportion of children overall who had elevated cholesterol (about 10%) with the proportion of children with elevated cholesterol who would not have been tested under current guidelines (about a third.)\n", "answer": 0}, {"article": "For an early version of the study abstract, click on \u201cContents,\u201d then \u201cVolume 44, No.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering here. And the story does a good job explaining the connection between Alzheimer\u2019s and memory loss.", "answer": 1}, {"article": "More adults and kids taking Prozac, known generically as fluoxetine, had at least a 50 percent improvement in scores on depression tests after six weeks compared to those assigned to take a placebo pill.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\n\u201cThere are alternative treatments for depression that also produce about the same symptom reduction as the drugs do, but without the risk of side effects,\u201d Kirsch added, including psychotherapy and exercise.\nThe benefits were seen regardless of how severe patients\u2019 symptoms were before starting treatment.\nIf five or more patients need to be treated with an antidepressant for one to substantially improve, most don\u2019t get much out of it, he pointed out.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering about depression here.", "answer": 1}, {"article": "The 12 poses, by their English names, were tree, triangle, warrior II, side-angle, twisted triangle, locust, bridge, supine hand-to-foot I, supine hand-to-foot II, straight-legged twist, bent-knee twist and corpse pose.\nBut all told, the team concluded, the results may lend support to Dr. Fishman\u2019s long-held belief that yoga can help reverse bone loss.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nA decade after the start of the study, bone density measurements were again taken and emailed to the researchers; many participants also had repeat X-rays done.\nFurthermore, a special study of bone quality done on 18 of the participants showed that they had \u201cbetter internal support of their bones, which is not measured by a bone density scan but is important to resisting fractures,\u201d Dr. Fishman said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No evident disease mongering in this story, except to say that osteoporosis and it\u2019s precursor osteopenia are often heavily mongered diseases simply because bone density is one of many risk factors for hip fractures (that is treatable with drugs) but it is not the most important one. In fact, some argue that bone density is such a low predictor for hip fractures it is worthless as a measure of bone health and simply shouldn\u2019t be employed.", "answer": 1}, {"article": "In skin testing, a practitioner makes rows of pricks on a patient\u2019s back or forearm so allergen-containing extracts can seep into the skin.\nBecause the test comes with a small risk of a serious reaction, it should not be performed in very young children and pregnant women, among others.\nWhile most allergy patients are seen by these generalists, he says, many allergies are not adequately diagnosed.\nBecause they were not considered very sensitive, physicians were left with a lasting impression that blood testing was inferior to skin testing.\n(And many sufferers of seasonal and pet allergies know what they\u2019re allergic to, so they don\u2019t need a diagnosis.)\n", "question": "Does the story commit disease-mongering?", "explanation": "The story commits disease mongering by not emphasizing that the blood and skin tests are only used in those with severe allergies. Most people with common pet or seasonal allergies will not require this kind of testing. Furthermore, the story overstates the risk that children with allergies have of\u00a0developing respiratory problems and asthma later on.", "answer": 0}, {"article": "Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer\u2019s disease, a Mayo Clinic study published this month in the Journal of Alzheimer\u2019s Disease found.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nIn the study, women with APOE e4 \u2014 one form of the most common gene associated with late-onset Alzheimer's disease \u2014 had lower levels of amyloid deposits.\nThe researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.\nThe oral treatment was not associated with lower amyloid deposition.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t exaggerate a condition. It states that declines in estrogen associated with menopause \u201cmay\u201d be associated with an increased risk of dementia. Unfortunately, that doesn\u2019t give readers a feel for the robustness of the relationship, or for the evidence supporting it.", "answer": 1}, {"article": "In 2016, he was ranked the No.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\nThis large scale randomized trial will test whether Plaque HD\u00ae reduces risks of heart attacks and strokes.\nThe original research from the landmark Physician's Health Study, in which Hennekens was the founding principal investigator, was the first to demonstrate that hs-CRP predicted future heart attacks and strokes.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release illustrates a recurring problem with disease-oriented rather than patient-oriented evidence. The release ties dental plaque and hs-CRP test levels more tightly to heart attacks and strokes than is justified. It begins by stating, \u201cFor decades, research has suggested a link between oral health and inflammatory diseases affecting the entire body \u2014 in particular, heart attacks and strokes.\u201d But it doesn\u2019t explain how nuanced those links are. Indeed, the value of CRP testing is hotly debated. It is typically recommended only for people having a hard time deciding whether or not to begin statin drug treatment. The release strongly (and improperly) implies that everyone, regardless of their individual heart disease risk, would benefit from something that lowers hs-CRP levels. Indeed, almost 40 percent of the trial participants were dropped from the hs-CRP comparisons because their levels were already low. If researchers decided that more than a third of the trial participants were unlikely to see any meaningful reduction in their hs-CRP levels, the release should have noted that many people have no reason to think that this product could reduce their heart disease risk.", "answer": 0}, {"article": "The median age was 75 years (range 41to 94).\n\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\nThe study evaluated safety and efficacy outcomes of 1,083 patient reports collected in a multi-institutional database.\nTo date, they have accumulated data on close to 1,200 such patients and identified medical and technical factors that affect tumor control and toxicity.\nTheir collective experience is among the largest multinational series of patients treated with image-guided SBRT to date.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release. But we also don\u2019t know the natural history of early stage lung cancer in this population. Does treatment really extend the quantity or quality of life? We expect it does, but nothing presented here supports SBRT compared to no treatment or other active treatments.", "answer": 1}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\nOverall, the MRI detected 25 of 27 cancers, DeMartini said.\nWhile the society recommends neither for nor against MRI imaging for those with a personal history of breast cancer, he said it regularly reviews study findings to determine if the guidelines need updating.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story does say that the American Cancer Society does not currently recommend MRI scans for most women with a history of breast cancer. However, it does not give readers the information they need to understand who this study is relevant to. It does not provide key details about the women who participated in the study. Was there something unusal about their cases that prompted them to get an MRI scan of their breasts? The researchers reported that 3 percent of the women with a personal history of breast cancer were found to have another tumor. That number seems quite high. The story should have told readers more about the women in the study and how they compare to the average woman who has had treatment for breast cancer. And again, it should not allow researchers to claim that MRI adds anything to conventional mammography when this study did not involve any such comparison.\n", "answer": 0}, {"article": "\u201cIt is further proof that aspirin is, by a long way, the most amazing drug in the world,\u201d he said.\nAlastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists\u2019 understanding of how to prevent cancer.\nPeter Elwood, an expert on aspirin from Cardiff University\u2019s medical school who was not involved in this study, described aspirin as \u201ca remarkable drug.\u201d\n\n\u201cThis risk of a bleed is so small compared to the benefits,\u201d he told reporters.\nThe findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story highlights suggestions that everyone over 40 begin taking aspirin in order to reduce the risk of many types of cancer, while minimizing concerns about the limitations of this study and the risks associated with aspirin. The voices included in this story form a cheering section for the universal use of aspirin.", "answer": 0}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nHaving proved that it was neural stem cells that were important for ageing, the scientists ran further tests to work out what the cells were doing.\n\u201cHowever, if the mechanism is fundamental, you might expect to see effects when an intervention is based on it.\u201d\n\nPrevious experiments had already hinted that the hypothalamus, an almond-sized part of the brain in humans, played some role in the ageing process, but what it was remained unclear.\nThe stem cells are known to form fresh brain cells in youth, but the process slows down dramatically in adults.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t appear to commit disease mongering, though it could have pointed out that aging in and of itself is not a disease.", "answer": 1}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story commit disease-mongering?", "explanation": "The story engaged in subtle disease mongering because in its discussion of the use for this new product to treat \u2018blocked blood vessels\u2019 it failed to acknowlege that in fact, national guidelines don\u2019t recommend the use of stents to treat all\u00a0blocked coronary arteries, only those through which flow is occluded 70% or more.", "answer": 0}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\nOverall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release.", "answer": 1}, {"article": "increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\nShe said babies in her study might have received more DHA than those in this study.\nAnd the new study showed small reductions in postpartum depression in women with histories or high risk of depression.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.\u00a0 Good quotes from chief of maternal-fetal medicine at a leading Boston hospital:\u00a0\u201cI think the market is running way out in front of the science.\u201d", "answer": 1}, {"article": "The women with hysterectomies who used estrogen alone had a 23 percent lower risk for breast cancer compared with those who had taken a placebo.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\nDr. Rowan Chlebowski, another author of the study and a medical oncologist at Los Angeles Biomedical Research Institute, said the findings underscored the fact that the risks and benefits of menopause hormones change depending on a woman\u2019s health status, her age and the type of hormone used.\nBut the data are reassuring for millions of middle-aged women without a uterus who take estrogen to relieve hot flashes and other menopause symptoms.\nAlthough all the women in the estrogen study stopped using the treatment in 2004, the investigators have continued to monitor their health, as is typical in large clinical trials.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does a good job of discussing a variety of risks without exaggerating any of them. If anything, they may exaggerate the benefits in the headline.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Gestational diabetes increases the mother\u2019s chances for high blood pressure disorders of pregnancy and the need for cesarean delivery, and the risk for cardiovascular disease and type 2 diabetes later in life.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\nThe test is not currently recommended to diagnose gestational diabetes at any point in pregnancy.\nIn the current study, researchers evaluated whether the HbA1c test (also called the A1C test), commonly used to diagnose type 2 diabetes, could identify signs of gestational diabetes in the first trimester of pregnancy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering, but no data about frequency of the disorder, either.", "answer": 2}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nThat study found a benefit when 5-Hour Energy was compared to a placebo like flavored water, she said.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nMs. Lutz, the Living Essentials spokeswoman, said the bold \u201cNo Crash Later\u201d statement on product labels was followed by a special mark.\nBut she declined to say why the results of the study, which was apparently conducted five years ago, had not yet appeared.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Trials were conducted on nine healthy individuals in a blinded comparative study on absorbable versus fermentable carbohydrates.\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\nThe vitamin pill-sized capsule, currently being commercialised by Atmo Biosciences, provides real time detection and measurement of hydrogen, carbon dioxides and oxygen in the gut.\nStudy lead and capsule co-inventor Professor Kourosh Kalantar-zadeh said the results showed high sensitivity and signal-to-noise ratio in measuring the concentration of intestinal hydrogen, providing valuable information at the site of intestinal gas production.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release makes it sound like there is an epidemic of undiagnosed gastrointestinal disease occurring\u00a0worldwide:\nOf the one-in-five people worldwide who will suffer from a gastrointestinal disorder in their lifetime, almost a third remain undiagnosed due to lack of reliable tests available to gastroenterologists.\nBut the news release doesn\u2019t provide any source for this questionable claim.\nMoreover, the release suggests that that this technology will help \u201cdiagnose many gut disorders\u201d when, in reality \u2014 even if it does get marketed (like breath testing) \u2014\u00a0 it will likely only be applicable for a very short list of very uncommon gastrointestinal ailments listed HERE [Source: Johns Hopkins Medical School].", "answer": 0}, {"article": "But high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nAnd he says other people with high blood pressure should follow his lead.\nWhen blood pressure rises, it strains the tiny blood vessels that keep brain cells alive, Koroshetz says.\nKoroshetz is using all of these approaches.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story strongly suggets that people should take blood pressure medication to lower their risk of dementia. The evidence in the story wasn\u2019t strong enough to cross that line.\nAt the very least, the story should have provided links to the studies in this sentence: \u201cAt least two large studies have revealed an alarming trend among stroke patients.\u201d\nIt\u2019s also worth noting that the threshold for treatment is under debate, with some saying that blood pressure should be even lower than 130/80.\u00a0New suggestions like this \u2014 that BP control can lower dementia risk \u2014 may amplify such concerns by driving even more people in for treatment without a full grasp of the tradeoffs between potential benefits and potential harms.", "answer": 0}, {"article": "Corticosteroids are involved in a wide range of physiological processes in the body, including regulating metabolism, blood pressure and helping the body to cope with physical stress.\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\nThe researchers tested the therapy in a small group of patients with Addison's disease.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nThe therapy could help people with conditions such as Addison's disease and congenital adrenal hyperplasia, who need steroid treatment to avoid the risk of potentially fatal illness during physical stress.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The researchers make it clear that they are not trying to cure a health problem but, rather, seek to offer a safer treatment regimen for individuals with adrenal gland disorders.", "answer": 1}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\nBut conventional germicidal lamps aren\u2019t safe for humans to be around.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n\u201cThere has been no way of killing viruses in the air in public spaces, and this is an approach that may solve that problem.\u201d\nNow, Brenner and his colleagues have show that UVC light can effectively kill airborne influenza.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "The average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\nWells said Tehrani\u2019s team appeared to have hit upon a \u201cfairly accurate algorithm\u201d for predicting menopause.\nBut said it would be important to see if the method could also help predict the time when fertility effectively ends.\nThe test, which measures levels of a hormone produced by cells in the ovaries, was able to predict the age at which women reached menopause to within an average of 4 months, according to data to be presented at the conference of the European Society of Human Reproduction and Embryology in Rome on Monday.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. The story should have also avoided referring to women who want a career before having babies to know how long to wait. \u00a0Having a career does not preclude having a family, biological or otherwise. ", "answer": 1}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nAt 14, MS-13 was his family.\nHere\u2019s how he got out.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\n", "question": "Does the story commit disease-mongering?", "explanation": "The natural history of Parkinson\u2019s or its variability are not presented", "answer": 0}, {"article": "\"We didn't expect that at all,\" Dackis says.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\nHundreds of cocaine users are testing whether that legal pill, called modafinil, could help them kick the addiction, and there's early evidence that it may.\nAddiction specialists gave it a look because even though modafinil isn't a classic stimulant, it triggered something in the brain to also improve patients' mood, energy levels and ability to concentrate _ effects that might counter cocaine withdrawal.\nIn a small safety study to ensure that modafinil didn't make cocaine worse, some users found the once-a-day pill blocked that high.\n", "question": "Does the story commit disease-mongering?", "explanation": "No real evidence of disease mongering. The drug is promoted here to treat cocaine addiction and the incidence of this addiction is reported at 1.5 million in the U.S., however only about 250,000 were in substance abuse treatment (Substance Abuse and Mental Health Services Administration).", "answer": 1}, {"article": "Harder\u2019s PSA was 9.\nThat\u2019s one of our strengths.\u201d\n\nYu has seen how MRI technology has changed prostate patients\u2019 care.\nHis doctor recommended the traditional next step: a transrectal ultrasound (TRUS) biopsy, which involves taking random tissue samples from 12 cross sections of the prostate.\nMuch like someone would have an MRI to investigate the cause of back pain, the technology gives doctors eyes on what is happening in prostate tissue.\nWhen Yu started prostate MRI screening in 2011, his team performed about 50 scans per year.\n", "question": "Does the news release commit disease-mongering?", "explanation": "While prostate cancer is serious, this news release seems calculated to instill fear. It omits some important facts, such as that PSA levels often fluctuate and can be elevated for reasons that have nothing to do with prostate cancer. In fact, only about 25 percent of men who have a biopsy due to an elevated PSA level actually have prostate cancer, according to\u00a0cancer.gov.\nRelating the story of a patient whose cancer was diagnosed with an MRI after standard biopsies were inconclusive, the news release says other patients who continue to \u201chit a brick wall with negative results from TRUS biopsies yet persistently high PSA levels may not be as fortunate.\u201d A clinician is quoted saying: \u201cIf you do not have this kind of advanced imaging, sometimes a patient runs into a situation when a tumor can\u2019t be found and treated because it\u2019s too late \u2014 it has already metastasized. He ends up diagnosed with cancer only after the tumor has spread to his bone or lymph nodes years later.\u201d\nThe statement, \u201cWhen caught early, prostate cancer is highly treatable,\u201d is also troubling. In fact, prostate cancer does not always need to be treated, and treatment can result in long-term sexual side effects as well as urinary and bowel problems.\nTo avoid disease mongering, the release could have clarified that an elevated PSA test does not always identify cancer. Men can have elevated levels without cancer. Some of those with an elevated PSA who undergo an MRI will have a negative test \u2014 just like a negative biopsy.", "answer": 0}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\nBut is it something that we are in position to sort of ramrod down people's throats?\nHe's not only a dad, he's an expert on pediatric infectious diseases at the University of Chicago.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the annual number of deaths from cervical cancer. The story could have provided more context for these numbers \u2013 for example, how common HPV is and how rare it is for HPV infection to lead to cervical cancer.", "answer": 1}, {"article": "Amgen reported just $40 million in third-quarter sales.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\nThe primary goal also included need for a new artery-clearing procedure and hospitalization for angina.\nBut those who control budgets wanted concrete proof that the drug could actually reduce the risk of heart attacks and death before making it easier for patients to get the medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t appear to be disease mongering. We do wish it had included some statistics on the prevalence of heart disease, which is something the news release did.", "answer": 1}, {"article": "Co-authors on the paper, all from Boston University, are T.A.\nThis device for making vitamin D is ideally suited for patients with fat malabsorption syndromes including inflammatory bowel disease and gastric bypass surgery.\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\nResearch published today in Scientific Reports shows that light from RayVio's 293nm ultraviolet (UV) LED is more efficient than sunlight at producing vitamin D3 in skin samples.\nTyler Kalajian and his research team, led by Dr. Michael F. Holick, Ph.D., M.D., and supported by Boston University School of Medicine and a Boston University Ignition Award, found that skin samples exposed to RayVio's UV LED for just 0.52 minutes produced more than twice as much vitamin D3 as samples exposed to 32.5 minutes of sunlight.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Without stating the source or elaborating further, the release states that 75 percent of teens and adults in the US are vitamin D deficient. However, noted experts have disputed high claims of deficiency as being a misinterpretation of Institute of Medicine nutrition guidelines.\nBeing vitamin D deficient in itself is not a disease. It can lead to a loss of bone density, contributing to osteoporosis and fractures. Severe vitamin D deficiency in the US is rare, and the effects of vitamin D on other conditions need to be investigated further.\nFor these reasons we rate this Not Satisfactory for disease mongering.", "answer": 0}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nPhotophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\nWe believe the use of the colored glasses that provide photophobia mitigation has added benefits superior to dark sunglasses, especially for indoor lighting.\"\n\"What is needed is a light mitigation strategy that can be readily employed indoors, which can optimize relief in those who suffer from photophobia, or light sensitivity.\"\n\"We believe that an athletic trainer, in consultation with team physicians, may find it useful to apply this photophobia assessment and recommend colored glasses to his or her athlete,\" Clark says.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We did not find any disease mongering in the piece. Concussion and TBI numbers are very tricky because so few concussions are actually captured. TBIs are mostly tracked through ER visits. The CDC puts the TBIs that lead to ER visits at 2.8 million annually. So given that there are likely more mild concussions than true TBIs, this puts the 3.8 million number into conservative territory \u2014 if not well below where it should be.", "answer": 1}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nWhen Breteler\u2019s team considered a number of other factors \u2014 including participants\u2019 age, education, weight, and smoking and drinking habits \u2014 high vitamin E intake was linked to a one-quarter reduction in dementia risk.\nAnd it supports findings from some previous research that dietary vitamin E, in particular, might be related to a lower risk of dementia.\nIt is unlikely that people could get too much vitamin E from food.\nHowever, the new study followed participants for a longer period than most previous studies on antioxidants and dementia.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of dementia in this story.", "answer": 1}, {"article": "In the study, men taking an angiotensin receptor blocker had a 24 percent lower incidence of dementia than those taking other cardiovascular drugs.\nThe risk was nearly halved for those taking both angiotensin-targeting drugs.\nWolozin said that it's not clear why the drugs would have a beneficial effect on the brain, but improved blood flow probably plays a role.\nCaution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.\nCalled angiotensin receptor blockers, these drugs have a greater protective effect against dementia than ACE inhibitors, the study found.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no overt disease-mongering of dementia in the story. ", "answer": 1}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story commit disease-mongering?", "explanation": "It is not clear from the story what the disease is. Stress is mentioned, but so is depression, asthma, anxiety, insomnia, etc.", "answer": 0}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nHowever, it\u2019s important not to think of them as cheat days.\nThe dieters ate enough calories to maintain their weight during the off period.\nWhile frustrating, it\u2019s one of our natural survival mechanisms to prevent potential starvation.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering; the article did a pretty good job of noting the ups and downs of weight loss schemes.", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story commit disease-mongering?", "explanation": "This story including many laundry lists of symptoms ranging from the commonplace (sluggish) to scary (irreversible neurological problems) without appropriate context as to the incidence of the more serious problems or bothering to discuss that many of the problems described commonly result from problems other than vitamin B12 deficiency.", "answer": 0}, {"article": "In Belgium, engineer and nuclear physicist Yves Jongen is pioneering a new therapy that targets cancers with proton radiation; a therapy that offers precision and minimal side effects.\nWhile proton therapy is a giant step forward, it's not yet the magic bullet that clinicians are looking for.\n\"If you look at leukemia, which is cancer of the blood cells, there is nowhere to shoot -- it's all through the body.\"\nOther centers, however, are currently in development.\nAs the fame of the process has started to spread, some people have been taking desperate measures to get treatment.\n", "question": "Does the story commit disease-mongering?", "explanation": "A story such as this one, that makes only broad, sweeping claims about cancer \u2013 in general \u2013 never provided enough information about any one disease or condition to even warrant a satisfactory or unsatisfactory grade. \u00a0This can only be ruled as Not Applicable.", "answer": 2}, {"article": "The results have not previously been published or presented.\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\nThe field-friendliness and high specificity offered by the C-Tb test could allow for improved targeted treatment of M. tuberculosis-infected persons in also in resource-constrained settings, where IGRAs are too complicated to implement.\nThe new test measures the body's immune response to two TB antigens, EAST-6 and CFP10.\nThe cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not commit disease mongering.", "answer": 1}, {"article": "Another sensor, just approved by the F.D.A.\nEven with the help of an expert trainer from MiniMed, I found that injecting the catheter took much more dexterity than injecting one for a pump.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nOver the next six weeks of testing, I came down to earth as I realized that while the sensor enabled me to drastically cut my usual number of lows, it did not eliminate them.\nI kept following the recommendations of the embedded calculator, taking only very small amounts of insulin to bring my sugar level down.\n", "question": "Does the story commit disease-mongering?", "explanation": "The level of monitoring and use of injections as described in this article are beyond what has been tested in randomized controlled trials. ", "answer": 0}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\nIf the findings are confirmed by larger studies, they could vastly improve the ability to detect dementia in middle age.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nThere is currently no cure for dementia, though medication can be used to temporarily treat its symptoms.\n\"What we do know is that the blood supply in the brain is incredibly important, and that maintaining a healthy heart and blood pressure is associated with a lower risk of developing dementia,\" said Carol Routledge, Director of Research at Alzheimer's Research UK, who was not involved in the research.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. However, it is worth noting that the story does make one confusing statement. In a sentence immediately following a paragraph about dementia, the story states that \u201cIn the United States, the condition is the sixth biggest cause of death among all adults.\u201d That\u2019s inaccurate. Alzheimer\u2019s disease, specifically, is the sixth leading cause of death among all adults, according to the CDC. Dementia and Alzheimer\u2019s are lumped together by the UK\u2019s Office for National Statistics, which may have led to the confusion.", "answer": 1}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\n\"HCA shows promise as a potential therapy to prevent kidney stones,\" the researchers wrote.\nThis finding could lead to the first advance in the treatment of calcium oxalate stones in 30 years.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\nJeffrey Rimer, associate professor of chemical engineering at the University of Houston, was lead author of the study, published Aug. 8 in the online edition of Nature.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release is in line with common estimates when it states that up to 12 percent of men and 7 percent of women are affected by kidney stones, and that the incidence is rising.", "answer": 1}, {"article": "Labovitz also points out that the group of men who had fewer strokes were younger, had lower blood pressure and smoked less than the group more prone to stroke.\nTomatoes could contribute to reducing stroke in other ways, Willett says, because they are a good source of potassium, which is known to reduce blood pressure.\nIn other words, perhaps better health habits - not necessarily just the lycopene - lead to fewer strokes.\nThough the study looks promising, experts say that we can't necessarily give all of the credit to lycopene.\nIf we don't eat enough lycopene-packed foods, experts suspect too many free radicals get left in the body, damaging blood vessels by helping to form fatty deposits.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of stroke.\u00a0 However, the description of free radicals did sound a little alarming.\u00a0 They are natural byproducts of our biochemical processes.", "answer": 1}, {"article": "For instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\nThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\nThe investigation also showed that the benefits of taking aspirin increased over time.\nA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third.\nAny benefit for lung and esophageal cancer was limited to adenocarcinomas, which are most commonly seen in nonsmokers.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "The United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\n\u201cDietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke,\u201d wrote lead author Susanna Larsson, a professor at the Karolinska Institute in Stockholm, Sweden.\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\nMost of the studies allowed the researchers to rule out other factors, such as family history.\n\"It's again the diet per se, not any one individual component of the diet.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "N-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center\n\nN-acetylcysteine, when combined with group cognitive behavioral therapy (CBT), reduced symptoms of posttraumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.\nThis trial is the first to use NAC as a pharmacotherapy for PTSD and a broad range of SUDs.\nThe National Center for PTSD estimates that seven to eight percent of Americans will have PTSD at some point in their life.\nCurrently, there are no well-explored pharmacological treatments for patients with co-occurring PTSD/SUD.\nThe threshold CAPS score for diagnosis of PTSD is 50.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no obvious disease-mongering here. However, when the release notes that 7-8 percent of Americans have experienced PTSD at some point in their lives it could have been noted that the PTSD experienced by military veterans \u2014 leaving them \u2018difficult-to-treat\u2019 \u2014 is in a different category than what civilians might experience.", "answer": 1}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nDespite the mixed results, cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.\nBut Mr. Hoppenot said Novartis was taking a different path with cancer drugs, looking for treatments that would have a big, unmistakable impact on a small number of patients.\nIn two adults, the treatment did not work at all.\nBut at the 11th hour, a battery of blood tests gave the researchers a clue as to what might help save Emma: her level of one of the cytokines, interleukin-6 or IL-6, had shot up a thousandfold.\n", "question": "Does the story commit disease-mongering?", "explanation": "While certainly a terrible disease, acute lymphoblastic leukemia is\u00a0a treatable cancer. The 5-year survival rate\u00a0(percentage of patients who live\u00a0at least 5 years after their cancer is diagnosed), is more than 85%, according to the American Cancer Society, and many patients who survive that long are considered cured because relapse is rare. This story focused on one of the worst case scenarios, and didn\u2019t provide readers with this larger perspective.\nThe competing Philadelphia Inquirer story at least briefly referenced the 85% estimate.", "answer": 0}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\nThe article provides new insights into the disease's manifestations in the retina and information on the optical imaging system.\nThis clinical trial is reinforced by an in-depth exploration of the accumulation of beta-amyloid in the retina of Alzheimer's patients versus matched controls, and a comparison analysis between retina and brain pathologies.\nClinical trials were approved by Quorum Review, Seattle, Washington, (IRB00003226) and the U.S. Department of Health and Human Services (FWA00019841).\nThe study's first author, Yosef Koronyo, a research associate at Cedars-Sinai and a scientist and inventor at NeuroVision, said the latest findings cap a decade of study that has produced several landmark discoveries.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release.", "answer": 1}, {"article": "I was in New York last week, and the air was also not very clean.\u201d\n\nThe protective effect of ectoine was discovered by Prof Jean Krutmann and colleagues at the Leibniz Research Institute for Environmental Medicine, while investigating whether the molecule could protect skin against sun damage.\nBilstein said the inhaler could be useful around the world, as particulate air pollution is not just a European problem: \u201cEspecially in Asia \u2013 China in particular \u2013 the demand for such a product is even higher.\nRussell, who also lectures at Imperial College and Oxford University, said it might also be useful for the treatment of asthma, COPD and other lung diseases, not only prevention.\nBut research is also uncovering new impacts on health, including degenerative brain diseases such as Alzheimer\u2019s, mental illness and, this week, diabetes.\nThe impact of air pollution costs $5tn a year, according to a World Bank report published last week.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is a suggestion that all of us who live in cosmopolitan areas where particulate pollution is a problem will need to start and end our day with an ectoine inhaler or risk type 2 diabetes, Alzheimer\u2019s disease, COPD and a host of other maladies.\nAlso, the article should be mindful of statements such as the ones below, which may unintentionally incite fear in the public.\n\u201cOutdoor air pollution is a global health crisis that kills over 3 million people a year\u2026\u201d\n\u201cIn the UK, at least 40,000 people a year die prematurely from air pollution, with a cross-party committee of MPs calling it a \u201cpublic health emergency.\u201d\nThese types of statistics are, first of all, hard to wrap one\u2019s mind around. Overuse of them has numbed people to their impact and effect.", "answer": 0}, {"article": "Lack of F.D.A.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\napproval also means that insurers will not pay for treatment with Omacor.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nIt seems natural for Italy to be at the forefront of the fish oil trend and home to the largest clinical trials.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease-mongering. ", "answer": 1}, {"article": "Dr. Steve Hicks, senior author of the study and an assistant professor of pediatrics at Penn State College of Medicine, said the \"five microRNAs in saliva could predict with approximately 85% accuracy which concussed children would have symptoms one month later.\n(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\nDr. Jeffrey Kutcher, a neurologist and National Director of The Sports Neurology Clinic at The CORE Institute, said that \"work like this is important because it does provide potential for tests that can be helpful in the clinical setting.\"\nStill, \"the findings are promising, representing potential biomarkers for the diagnosis, recovery, and prognostic assessment of a sport-related concussion.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not commit disease-mongering. However, one paragraph discussing data from the Centers for Disease Control could be viewed as conflating concussions with all traumatic brain injuries (TBIs). The story notes that CDC data showed 2.8 million TBI-related visits to the emergency room, hospitalizations and deaths in the United States in 2013. Following this figure immediately is a reference to two-thirds of concussions occurring in children and adolescents; the structure thus suggests that all 2.8 million TBIs were concussions.", "answer": 1}, {"article": "Asthma on the Rise in U.S.\nThere is no cure, but most people can control their symptoms, reduce the severity of their disease, and prevent asthma attacks by avoiding asthma triggers and correctly using prescribed medicines, such as steroid inhalers, the CDC says.\nSymptoms completely disappeared in 94% of patients taking kampo herbs after an average of 16 days, Shimoide says.\nNorth American allergy experts tell WebMD that although they find the preliminary findings fascinating, further study is needed before they would recommend the herbs.\nIn contrast, about three-fourths of those taking standard asthma medications still had daily wheeze and other symptoms.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play.\u00a0 The story reported:\nThe number of people in the U.S. with asthma is growing. One in 12 people had asthma in 2009, compared with 1 in 14 in 2001, according to the CDC.\nThere is no cure, but most people can control their symptoms, reduce the severity of their disease, and prevent asthma attacks by avoiding asthma triggers and correctly using prescribed medicines, such as steroid inhalers, the CDC says.", "answer": 1}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\nResearchers say they\u2019ve developed a better way of scanning someone\u2019s heart to predict who is most at risk of a heart attack or stroke \u2014 long before conventional imaging methods can do it.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. The story stated that \u201cabout 750,000 Americans have a heart attack every year.\u201d", "answer": 1}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nRamsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nBut an updated look at the study indicates that heart disease patients who follow this advice may actually increase their risk for death.\nThe 458 male participants in the original study had been between the ages of 30 and 59 at enrollment, and all had a history of heart disease, with most having survived a heart attack.\nBut he also suggested that his team's rigorous look back offered valuable insights into how nutritional science has evolved.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of heart disease. The story is clear that the study involved middle-aged men with a history of heart disease and might not apply to other groups.", "answer": 1}, {"article": "Lung function got 10 percentage points better, on average, in people who got the drug compared with those taking a placebo.\nThe improvement at six months was still present almost a year after the study's start.\nBut these results, even with plenty of caveats, suggest the drug is on the right track.\nBut a key takeaway is that the medicine gets at a root cause of cystic fibrosis in some people rather than just relieving their symptoms.\nThe experimental medicine, taken twice a day, goes by the code name VX-770.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. It was clear that this was a study in people with a specific genetic mutation that affects only about four percent of CF patients.", "answer": 1}, {"article": "JACC is ranked No.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\nProgram, researchers in Madrid implemented a three-year healthy lifestyle intervention for 3 to 5 year olds that used their school, teachers and families to promote cardiovascular health through healthy diet, increased physical activity, understanding of the human body and managing emotions.\nThe largest positive changes in body fat were seen in the 3-year-old group that received three years of interventions.\nInterventions less than two years were not successful at reducing body fat.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this release.", "answer": 1}, {"article": "DOI: 10.1001/jamacardio.2016.4828\n\nCONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail)\n\nPart of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nThe study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\nWHO: Jerome Fleg, MD and Yves Rosenberg, MD, M.P.H., Division of Cardiovascular Sciences, NHLBI, NIH, are available to comment on the findings and implications of this research.\nHowever, a randomized study is needed to confirm these findings, according to the authors.\nIn addition to NHBLI, the study received funding from the NIH's National Institute of Diabetes and Digestive and Kidney Disease, the National Institute of Aging, and the National Eye Institute.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this release. But there\u2019s very little context about the disease either.", "answer": 2}, {"article": "New Jersey and Ohio were the first to participate statewide in the program.\nThe boxes are a new idea for many Americans.\nThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\nShe said the program was eye-opening for how much information she learned about how to prevent sudden unexpected infant death.\nThe boxes provide a clutter-free sleep space that has been shown to reduce accidental and unexpected deaths, she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "No serious adverse events were reported.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "Transcendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nMost doctors say meditation can\u2019t hurt you, but now there\u2019s reassuring evidence that it may help you as well when it comes to warding off disease.\nMost doctors say meditation can't hurt you, but now there's reassuring evidence that it may help you as well when it comes to warding off disease.\nIn the latest trial to address those limitations, however, meditation does appear to have an effect on reducing heart attack, stroke and even early death from heart disease, at least among African-Americans.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "Of those, 2,148 had taken lithium, 1,670 had used valproate, 1,477 had been on olanzapine and 1,376 had taken quetiapine.\nResearchers claim that although the drug does carry some health risks, its overall effectiveness, especially its ability to reduce self-harm and suicide, mean it should be much more widely used.\nThe lead author behind the research told the Guardian that widespread \u201clithium stigma\u201d among patients is leading to them receiving the wrong treatment and ending up admitted to hospital unnecessarily because their condition is not as well controlled as it could be.\nIt is seen by patients, and some psychiatrists, as a dangerous drug.\n\u201cDifferent people will find that different treatments help with managing their mental health problems.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease mongering. Given the seriousness of the disorder and its prevalence, we would have liked to have seen read more on how many people it affects.", "answer": 1}, {"article": "Doctor Challenges Cause Of MS And Treatment\n\nOne day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping.\nStecker says if he had it to do over again, he would have waited for more research.\nAlthough the doctor who treated him in New York found a significant blockage, he was unable to correct it, Stecker says.\nRobert Zivadinov of the Buffalo Neuroimaging Analysis Center in New York says that not only is the procedure unsafe and costly to many patients, it is impeding necessary research.\nBut he says he was eager to try something that offered him the first real glimmer of hope for a cure.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although there was no overt disease-mongering, the story focuses exclusively on the story of a patient who had an aggressive case of the disease. MS can manifest itself in a variety of different ways, and his experience is not representative of patients\u00a0with mild and slowly progressing MS. \u00a0Also, not everyone with MS has the vascular abnormalities discussed in this story, and so would presumably not benefit from this procedure. Finally, the story should have explained that MS is a condition characterized by flare-ups\u00a0that often get better by themselves, so it\u2019s hard to tell if\u00a0\u201cmiraculous\u201d recoveries are attributable to\u00a0the surgery or are\u00a0just the natural course of the disease for these patients.\u00a0A bit more context on these issues would have been helpful, but\u00a0we don\u2019t think the story deserved to be flagged for not including it.", "answer": 1}, {"article": "\"It's kind of amazing that something so simple could be an answer,\" Paul said.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\nOne local pediatrician said she wouldn't discourage parents from trying honey with their children, but more studies are needed to draw solid conclusions.\nThe study comes at a time when parents are on the lookout for new ways to give sick children relief.\nThe study was paid for by the National Honey Board, an industry-funded agency of the U.S. Department of Agriculture.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the prevalence of common colds.", "answer": 1}, {"article": "A biopsy involves the removal of tissue or fluids to test for disease.\nIn addition, image-guided biopsies are more accurate, Quencer said.\nFor these areas, open biopsies are easier to do and need less imaging guidance, Kwan's team noted.\nThat's an annual growth of 3 percent in number of biopsies, the researchers noted.\nThe report is published online and in the September print edition of Radiology.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable because no diseases were discussed in any detail. ", "answer": 2}, {"article": "\"It's just that the guidelines don't clearly let you use the tests from that one blood sample to make the initial diabetes diagnosis,\" she explained.\n\"Given these numbers, any abnormality of glucose should be regarded as sufficient reason to start preventative treatment with an education program, lifestyle change and first-line medication such as metformin.\"\nAccording to Bernstein, if only one diagnostic test were needed, \"this would mean that a follow-up visit would be a look at the treatment benefits -- rather than a confirmation of an abnormal glucose.\"\nCurrently, it's recommended that a blood test focused on elevated fasting levels of blood sugar (glucose) or a blood component called glycated hemoglobin (HbA1c) be confirmed with a second blood test at a follow-up visit.\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering, but the story would have been stronger with information about who should be screened. For example, the U.S. Preventive Services Task Force recommends checking for abnormal blood glucose as part of cardiovascular risk assessment in adults who are overweight and between 40 and 70 years old, and referring those with abnormal levels to intensive behavioral counseling.", "answer": 1}, {"article": "The second study, published in 2013, had a similar set up \u2014 37 people complaining of gastrointestinal problems, randomized into high-gluten, low-gluten and no-gluten groups.\nIt\u2019s hard to test for gluten sensitivities.\nIf you think avoiding gluten will make you feel better, there is a reasonable chance that it will \u2014 even if gluten is irrelevant.\nEveryone participating in the study was on a gluten-free diet.\nSomewhere in that gap, a diet fad is thriving.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "\u201cThis was far greater than expected.\n\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\nIn the MADIT-CRT trial, women were more likely to suffer heart failure caused by a viral infection of the heart, whereas in men, the condition is more often caused by blocked heart arteries, Moss said.\n\u201cOur finding was unexpected, but extremely important because this is the only heart treatment that is clearly better in women than men,\u201d Dr. Arthur Moss of the University of Rochester Medical Center, whose study appears in the Journal of the American College of Cardiology, said in a statement.\nWomen tend to have smaller hearts than men and Moss said the treatment works better in smaller hearts.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story ended with disease mongering about the 42 million American women \u2018living with heart disease\u2019 in a story about heart failure, which, while it may fall under the rubric of heart disease, is only a subset of the vast 42 million. \u00a0The story then went on to share that \u2018It\u2019 is the \u2018leading killer of women\u2019. Why not simply provide heart failure stats, and heart failure stats by gender?", "answer": 0}, {"article": "Separate strands of material become stronger when they link up.\n\u201cCreating a material that behaves like skin is very difficult,\u201d added Dr. Barbara Gilchrest, a dermatologist at the Massachusetts General Hospital who worked on the study.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\nIt lasted for 16 hours before it started peeling off, and smoothed out the eye bags that become so common as people age, they wrote.\nThe stuff can just be peeled off, or taken off with makeup remover, the researchers said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Given the tone of the piece\u2013lots of medical language and interviews with researchers\u2013and that it appeared in the NBC\u2019s\u00a0Health section, we feel this story disease-mongers a normal life event (aging).", "answer": 0}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story commit disease-mongering?", "explanation": "The piece does not engage in disease mongering.", "answer": 1}, {"article": "For more on stroke, visit the National Stroke Association.\nIn this study, patients were given the drugs within 4.5 hours after the onset of a stroke, Campbell said.\nBleeding into the brain, the most serious side effect of either drug, occurred in 1 percent of patients, regardless of which drug they received, Campbell said.\n\"It is likely to change stroke treatment guidelines and clinical practice.\"\nArora explained that tenecteplase is not widely used in the United States for heart attack patients because these patients are typically treated with angioplasty or heart bypass surgery.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nBut TMS is expensive.\nThe NeuroStar system resembles a dentist's chair.\nThen she agreed to a transcranial magnetic stimulation.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here", "answer": 1}, {"article": "There are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\nPublished in the Journal of Nutritional Biochemistry, the study involved feeding the different types of omega-3s to mice with a highly aggressive form of human breast cancer called HER-2.\nProf. David Ma has discovered that marine-based omega-3s are eight times more effective at inhibiting tumour development and growth.\nBased on the doses given in the study, Ma said humans should consume two to three servings of fish a week to have the same effect.\n\"Seeing the significant benefits omega-3s can have in combatting a highly aggressive form of breast cancer means omega-3s will likely be beneficial for other types of cancer.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release states that the HER-2 form of breast cancer \u201caffects 25 percent of women.\u201d That number seems over-inflated according to other sources.\nThe Mayo Clinic website states \u201cin about 1 of every 5 breast cancers, the cancer cells have a gene mutation that makes an excess of the HER2 protein.\u201d And Cancer Investigation journal put the number of women with HER-2 positive at 19% for women under 49 years and 15% for those over 50 years old.", "answer": 0}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\nIntriguingly, it appeared to be more effective among people with two copies of the APOE4 gene, a genetic combination that increases risk for Alzheimer\u2019s by a factor of 20 or higher.\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\nThe study was led by Dr. Paul Newhouse of Vanderbilt University and published in Neurology.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not resort to disease-mongering.\u00a0 Like the MSNBC story, though, it could have more clearly distinguished between mild cognitive impairment and forgetfulness.", "answer": 1}, {"article": "Source: Australian Bureau of Statistics, 2016, National Health Survey: First results, 2014-15, ABS cat.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\nNewswise \u2014 Thousands of people can take heart as new research from the University of South Australia shows a dairy-enhanced Mediterranean diet will significantly increase health outcomes for those at risk of cardiovascular disease \u2013 and it\u2019s even more effective than a low-fat diet.\nSimilarly, the Mediterranean diet (MedDiet) has been shown to deliver significant health benefits.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no evidence of disease mongering in this release. The release provides useful context on the prevalence of cardiovascular disease in Australia and globally.", "answer": 1}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nWhile there has been greater success in treating cancer, survivors may live many years with side effects after treatment.\nWhile some risk factors are well-known -- including age, diabetes and poor cardiovascular health -- whether a man suffers harsh side-effects is often chalked up to random luck.\nDoctors usually can\u2019t predict whether a man will suffer all or none of those side effects.\nIf you see a radiation oncologist he\u2019ll say oncology.\u201d\n\nDetermining what type of treatment a man should receive is only part of the dilemma of prostate cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering. Prostate cancer is the most frequently diagnosed cancer, most men are diagnosed at an early stage and subsequently undergo active treatments\u2013which carry substantial risks for complications. \u00a0However, the article could have cited estimates for the risk of erectile dysfunction following treatments.", "answer": 1}, {"article": "For more about corneal transplants, try the U.S. National Library of Medicine.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\nGriffith said a German study recently found that donated corneas cost about $2,500.\nIn the new study, researchers tested corneal implants that are \"biosynthetic,\" meaning they're created with the help of living tissues.\n\"However, there is a shortage of good quality corneas that can be used for transplantation.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story avoids disease mongering and actually presents a more conservative estimate of the number of people affected by corneal disorders. An estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.", "answer": 1}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story commit disease-mongering?", "explanation": "Presented an estimate for the number \nof people affected by lupus (1.5 million in the U.S.) as well as an estimate (5-10%) for the proportion of patients who did \nnot respond to standard treatment.", "answer": 1}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story commit disease-mongering?", "explanation": "This story engaged in disease mongering. \u00a0Cirrhosis of the liver is a serious condition and though its incidence appears to be on the rise in seriously obese children, liver disease should not be the top concern for parents of children who are overweight or simply obese. \u00a0The story made it sound as though all children with cirrhosis will require a liver transplant.\nIt presented data that exaggerate the prevalence and severity of the condition in children and provoke fear in the reader. The article says that 2 to 5 percent of kids over age 5 may have NASH, but then says as many\u00a0as 10 percent of children and half of obese children have it. \"It\" being a very mild and early form of the condition,\u00a0that may\u00a0or may not lead to long-term problems. Cirrhosis and the need for liver transplant remain very rare conditions in children. ", "answer": 0}, {"article": "JACC is ranked No.\nThey also looked a several early indicators of heart disease.\nThe mission of the College is to transform cardiovascular care and to improve heart health.\n\"Our findings highlight the link between worsening depression and cardiovascular risk and support routinely assessing depression in patients to determine heart disease risk.\n\"There are many patients with heart disease who also experience depression - we need to study whether encouraging them to exercise will reduce their risk of adverse outcomes.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release is good on this front. It does not commit disease-mongering of\u00a0cardiovascular diseases.", "answer": 1}, {"article": "\"I feel like I can accomplish what I want to accomplish.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nAccording to a study conducted by the Mayo Clinic that looked at one genetic test similar to many used in hospitals \u2014 GeneSight Psychotropic \u2014 symptoms of depression were reduced by 70 percent compared to treatments prescribed without genetic testing.\n\u201cOnce the genetic testing became available it provided Sarah with more than just physical relief,\" says Dr. Matthew B. Stanley of the Avera Medical Group in Sioux Falls, South Dakota.\n", "question": "Does the story commit disease-mongering?", "explanation": "The single patient profiled who took 23 different combinations is not representative of typical person with depression.\u00a0Also, the story said that \u201cmany\u201d people with depression experience severe side effects, but offers no data to back up such a claim.", "answer": 0}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nBut the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\n\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive.\nA next-generation implant deep in Jay\u2019s back stimulates her spinal cord, overriding her body\u2019s pain signals to give her some relief from the back pain that has plagued her for years.\nJay lays out the hows and whys of spinal stimulation, and she paints a vivid picture of a life in agony, a journey that has included skeptical doctors, plenty of painkillers and unanswered questions about the future.\n", "question": "Does the story commit disease-mongering?", "explanation": "The statement that \u201can estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain\u201d suggests that there are millions of Americans who could be lifted out debilitating misery with this technology. The story should have attempted to give an accurate picture of how many people could actually benefit.\u00a0\n The implication is that this procedure may be appropriate for many patients with chronic pain. Given that there is very little evidence to support this treatment as safe and effective, the thought of spending billions to place them in the millions of individuals mentioned is frankly scary.", "answer": 0}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\nI would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\nIt is designed for patients who have not had surgery.\nThe treatment, which includes several 20-minute procedures and rehabilitation, costs between $3,500 and $4,000.\nIt is less than half the cost of surgery but is rarely covered by insurance.\n", "question": "Does the story commit disease-mongering?", "explanation": "By describing a patient who \u201ccame crawling into my practice,\u201d the story crosses the line into disease mongering. This case represents an extreme example of herniated disc. Many patients are not as bothered by symptoms. The story also starts out by saying that this is a new treatment for herniated discs, but later claims that it can be used to treat a wide variety of back pain conditions. The story also does not explain that this treatment should not be used in people who have had back pain for less than a few months, for whom exercise and time would be the best course of treatment.", "answer": 0}, {"article": "Men with low-risk prostate cancer are currently put under active surveillance, where the disease is monitored and only treated when it becomes more severe.\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\nIn the trial, only 6 percent of patients treated with VTP needed radical therapy compared with 30 percent of patients in the control arm who were under active surveillance.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story shares the flaws of the news release it\u2019s based upon.\nIt says that prostate removal causes lifelong erectile problems, but this is not always the case. Nerve-sparing procedures can preserve potency for a substantial proportion of patients.\nIn addition, active surveillance is described as monitoring and treating only \u201cwhen\u201d the cancer becomes more severe. The correct phrasing would be \u201cif and when\u201d the cancer progresses, because many of these cancers will not progress.\nThe phrasing \u201ckills cancer\u201d in the headline is also questionable, as it sends a false message that low-risk prostate cancer needs to be eradicated. In fact, most men with small, isolated prostate cancers can live for years without treatment.", "answer": 0}, {"article": ".\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n\"Although this condition usually occurs in men older than 50 with a family history of the disease, anyone can have an abdominal aortic aneurysm,\" said Todd Vogel, associate professor and chief of the Division of Vascular Surgery at the MU School of Medicine, and lead author of the study.\nOf those who do get to a health facility alive, only about 50 percent survive.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We rarely ding stories on this criterion, but this one struck us wrong because of the mismatch between the first few sentences and what the science found. It says, \u201cRupture of an abdominal aortic aneurysm is one of the most dramatic medical emergencies a person can face. It usually strikes without warning, killing approximately 50 percent of those who experience it before they reach a hospital. Of those who do get to a health facility alive, only about 50 percent survive.\u201d Are you scared? Well, you probably are hoping that these researchers have found a way to save you from dying unexpectedly before you get to the hospital. But they haven\u2019t. Nor have they found something that is going to guarantee that you won\u2019t die once you reach the hospital, not if the aorta is already ruptured, although we must note that the release is confusing on this point because the provenance of the survival statistics is unclear. What\u2019s also confusing is that the release is conflating an enlarged aorta \u2014 which is a serious but manageable condition known as an\u00a0aortic aneurysm \u2014 with a ruptured aorta, which is what leads to people bleeding to death at high rates. The statins might be helpful for people who have an aneurysm that\u2019s surgically repaired; they do nothing in the event of a rupture. In all, the picture painted is far grimmer than the actual context necessary for this release, which is that if people have an aortic aneurysm they might benefit from statins.", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story commit disease-mongering?", "explanation": "No obvious disease mongering. The story accurately represents the prevalence and seriousness of breast cancer.", "answer": 1}, {"article": "Foxman B, Barlow R, D'Arcy H, Gillespie B and Sobel JD.\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\n\"While recommendations for dosage and duration of treatment require further study, the efficacy of the medicinal properties of cranberry products has been well-established.\"\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\na total of 28 studies showing results from nearly 5,000 patients were considered.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release refers to a UTI as a \u201cpotentially debilitating infection,\u201d but given that UTIs can lead to kidney damage or sepsis, that\u2019s not inaccurate.", "answer": 1}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story commit disease-mongering?", "explanation": "The story never\u00a0suggests that fetal chromosomal abnormalities or maternal cancers uncovered by the blood tests are a major threat. Unlike the CBS story, WSJ notes that the cases identified in the study were culled from more than 100,000 samples and that such findings are \u201crare.\u201d The tone of the story is cautious and it quotes experts who call for further studies and conversations about the current and potential use of diagnostic prenatal blood testing.", "answer": 1}, {"article": "According to Andrew Lee, co-founder of Medherant, \u201cwe\u2019ve only been in the lab about 12 months, but in the 12 months we\u2019ve essentially assessed about 90 percent of the drugs that are currently available as either creams or patches.\nHe said Medherant\u2019s technology would eliminate most side effects created by oral medication.\nHaddleton says the technology has exciting potential for other medications, such as opioid painkillers.\nAn ibuprofen patch that delivers the painkiller directly through the skin to the site of pain, at a consistent dose for up to 24 hours, has been developed by UK researchers.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "The women who ate more berries also tended to eat healthier overall, consuming more vegetables and fruits than those who didn\u2019t eat as many berries; but when the scientists broke down the women\u2019s diets, they found that the highest consumers of berries even had a lower risk of heart attack compared with women who still ate plenty of fruits and vegetables but fewer berries.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nThe researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\nIt is a powerful message that we can prevent cardiovascular disease by what we eat.\u201d Something worth remembering the next time you\u2019re in the produce aisle.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "\"Many labs are looking at this.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nThe only definitive way to diagnose the disease is by direct examination of brain tissue after the patient dies.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\nThe research results on the new test are published online in PLoS ONE.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story does not exaggerate the extent or severity of Alzheimer\u2019s Disease. However, it might have been helpful to include some description of the sort of individual who might consider using this sort of test. \n\n\nStories like this need to be clear that since there is no meaningful treatment currently available for Alzheimer\u2019s disease, many individuals may not want to be burdened with the prospect of impending dementia when there is no known way to do anything about it. The story would have been better if rather than focusing on individuals and the fearful prospect of Alzheimer\u2019s, it had given more attention to the most likely near-term use for Alzheimer\u2019s tests: as aids to researchers studying potential treatments in controlled trials.\n", "answer": 1}, {"article": "HPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nThe vaccine is recommended for optional use in boys and men.\nBoth of these vaccines are recommended to prevent cervical cancers.\nThe Gardasil vaccine has also received FDA approval for prevention of genital warts.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\n", "question": "Does the story commit disease-mongering?", "explanation": "A thoughtful and careful discussion of the potential risk for genital warts, and the still-uNPRoven connection between the viruses and the development of penile and anal cancers in men. All of this does relate to the number of sexual partners, which the storyr explains.", "answer": 1}, {"article": "Lung cancer is the most common cause of cancer death in the U.S. for men and women.\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\nMuch work lies ahead in determining whether the compound and related ones will prove to be effective therapies, but the researchers say their discovery demonstrates the power of screening specially designed compounds against cancers \"with certain genetic quirks.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The article presents accurate data on lung cancer mortality and NSCLC from\u00a0the American Cancer Society.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "Both spine conditions reported in the news story are real problems for many people. There are no obvious elements of disease-mongering in the story, though its handling of degenerative spondylolisthesis (DS) might lead some readers to conclude that DS is a dire problem requiring surgery, rather than a predicament that might reasonably be treated either surgically or nonsurgically, depending on a patient\u2019s tolerance for risk and preferences. The majority of patients receiving nonsurgical care showed \u201cmoderate\u201d improvement, a fact the news story never mentioned. (See also \u201cEvidence\u201d and \u201cQuantification of benefits\u201d below.) ", "answer": 1}, {"article": "Researchers are developing decision aids to guide physicians and consumers beginning to struggle with lung cancer screening.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nIn fact, if screening finds cancer, some seniors won\u2019t withstand the surgery, usually a lobectomy, that may cure it.\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\n", "question": "Does the story commit disease-mongering?", "explanation": "In some ways, this story is an example of a way to avoid disease-mongering. Because any Medicare-approved procedure will, by definition, be carried out on elderly individuals, the story\u2019s reflections on \u201ccompeting mortality\u201d\u2014the tendency for older folk to be saddled with multiple chronic diseases\u2014emphasizes the importance of situating lung cancer among the elderly in a larger matrix of health issues. Lung cancer is clearly an important disease, but, as one physician/researcher noted in the story, \u201cIf I find a teensy lung cancer in a 77-year-old with heart disease, I may not have done him any favor.\u201d", "answer": 1}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\n\u201cOur results highlight the need to adopt this practice at acute care hospitals across the nation,\u201d said Dr. Smith.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\nConsultation with the palliative care team included establishment of goals of care, advance care plans using standardized communication protocols, transition planning and symptom assessment and treatment using the Edmonton Symptom Assessment Scale (ESAS).\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release. The severity of terminal cancer could hardly be exaggerated. The release provides useful background on what palliative care is and what it entailed at this hospital.", "answer": 1}, {"article": "Currently, the U.S. Preventive Services Task Force recommends that biennial screenings start at age 50 for most women, while the American Cancer Society advises that annual screenings begin at age 45.\nClearly, the earlier a breast cancer is diagnosed, the less treatment that will be required.\nAnd Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, noted that this was an observational study that only looked at the experience of one institution.\nAnd the women who were screened earlier had smaller tumors.\nBut only 29 women fell into the \"never had a mammogram\" group.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not directly engage in fear-mongering. However, some of the quotes advocating for earlier and more frequent screening play into a scenario that breast cancer is lurking in every woman.\nA discussion of what a woman\u2019s average lifetime risk is would have been helpful.", "answer": 1}, {"article": "\"The work by [first author] Price et al.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\nThe study is in the May 1 issue of Cell Metabolism.\n\"Our paper found you absolutely require the SIRT1 gene for resveratrol to improve the metabolism of the mice,\" Sinclair said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable.\u00a0 Unless we\u2019re talking about aging in mice.", "answer": 2}, {"article": "Our new test is therefore a potential game changer,\" says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\nProfessor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, said: \"Detection of this tumour marker may also play a role in a simple liquid biopsy to monitor disease stage and treatment.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The scope and diagnostic challenges of ovarian cancer are appropriately included.", "answer": 1}, {"article": "Measuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\nThe findings may reduce the number of unnecessary treatments prescribed to otherwise healthy girls.\nLifestyle changes and different exercise-related signals that regulate the secretion of irisin could provide a potential option for the management of PCOS.\nThe cause of PCOS is unknown and there is currently no cure for the condition.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release says that PCOS \u201cis a common endocrine disorder affecting up to 12% of women\u201d \u2014 and it\u2019s not clear where they got the 12 percent number from. However, that\u2019s not too far off from numbers we\u2019ve seen elsewhere (as high as 10 percent, via NIH), and the language throughout the remainder of the release is responsible.", "answer": 1}, {"article": "Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\n\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\nNEW YORK (Reuters) - Blood injections, especially of platelet-rich blood, into the affected area help relieve the pain associated with \u201ctennis elbow\u201d where other treatment methods have failed, according to a Greek study.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story nicely avoids disease mongering and, right in the lead, explains that this treatment would work best in patients \u201cwhere other treatment methods have failed\u201d.", "answer": 1}, {"article": "\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nIn the report, the researchers describe endoscopic procedures to position electrodes in the sinus cavities of five patients with an intact ability to smell.\nThere are currently no proven therapies for these cases.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release describes the potential effects of anosmia fairly accurately, consistent with a 2013 study on the consequences of the condition. It also puts the disease in context, describing how many people are estimated to be affected by smell loss.", "answer": 1}, {"article": "Unlike common polyps, they tend to be flat and the same color as the colon lining.\nThe DNA stool test methods were developed at the Mayo Clinic.\nIt's important for people with IBD because they are at much higher risk for colorectal cancer than the general population.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\nTUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering. ", "answer": 1}, {"article": "\"There's always kind of a 'trend of the week' that you had to go and get tested for and rule out, and at the end of the day you don't feel better,\" she said.\nMaking it worse for many patients, there hasn't been a conclusive test to diagnose what's wrong with them.\nBut that could finally change with the introduction of two simple new blood tests for spotting the disease.\nWithout proof of a physical cause, some doctors considered IBS a psychological disorder.\nShe got the new blood test to confirm her diagnosis, and when it came back positive, she said she felt a sense of relief knowing IBS wasn't all in her head.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story says IBS affects 25 million to 45 million people in the U.S. While this may be true, the test we\u2019re talking about isn\u2019t a test for IBS in general \u2014 it\u2019s a test for those with the diarrhea predominant version. It\u2019s not clear how many people this amounts to, but according to this study, less than half of the people with IBS meet the criteria for the diarrhea-predominant version. The story exaggerates the potential impact of the test in a way that promotes a commercial interest, so we\u2019ll flag it for disease mongering.", "answer": 0}, {"article": "Gretchen A. Brenes, Ph.D., of the Wake Forest School of Medicine, Winston-Salem, N.C., and coauthors compared telephone-delivered cognitive behavioral therapy (CBT) with telephone-delivered nondirective supportive therapy (NST) in a randomized clinical trial of 141 adults 60 or older with generalized anxiety disorder.\nThis work was supported by grants from the National Institutes of Health and funding from the Taylor Family Institute for Innovative Psychiatric Research.\nThis work was funded by a grant from the National Institute of Mental Health.\nTelephone CBT consisted of up to 11 sessions (nine required) and focused on, among other things, anxiety symptom recognition, cognitive restructuring, relaxation, coping statements and problem solving.\nAt four months\u2019 follow-up there also was greater decline in self-reported GAD symptoms and depressive symptoms among participants in the telephone CBT, according to the results.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not demonstrate disease mongering.", "answer": 1}, {"article": "\u201cSome men go to the bathroom several times a night, get right back to sleep and are not bothered,\u201d he said.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\nNor does it lead to cancer.\nUrological experts are beginning to rethink treatments, too, based on symptoms and how much a man is bothered by them.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\n", "question": "Does the story commit disease-mongering?", "explanation": "While there was clear that benign prostate hyperplasia was not life threatening and did mention that there is a difference between symptoms and being bothered by symptoms, the story was strongly suggestive that postponing active treatment could have dire consequences without backing this up with information about how commonly serious problems develop.\nAdditionally, the discussion of disrupted sleep was rather specious. Treatments rarely completely eliminate symptoms so the problem of getting back to sleep will still be present.\u00a0 The comment that \"many doctors are now urging men to become proactive\" is difficult to interpret.\u00a0 What data support this statement, how many doctors are there, and who are they?\u00a0 Professional guidelines remain relatively conservative, recognizing that the truly bad outcomes are still relatively uncommon.\u00a0", "answer": 0}, {"article": "SAMe may influence the expression of genes involved in depression or alter the function of different receptors and structures that transport neurotransmitters in the brain.\nDr. Nelson, who was not involved in the Harvard study, said the results need to be replicated in a larger study, and that more information is needed on dosing, side effects and long-term treatment with SAMe, among other things.\nThe research offers hope to patients who haven\u2019t been helped by traditional antidepressant treatment.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\nDr. Papkostas, Dr. Nelson and other researchers involved in the study all disclosed several financial relationships with makers of prescription antidepressants.\n", "question": "Does the story commit disease-mongering?", "explanation": "We liked how the story restricted the target population to nonresponders. However, we slap its wrist because it said the study was in adults with depression who failed antidepressant treatment. It was actually major depressive disorder and failure of 6 weeks adequately dosed with a specific class of SSRIs. \nFurthermore, it defines \u201cnonresponders\u201d as patients for whom \u201cantidepressants don\u2019t eliminate symptoms.\u201d Eliminate is too strong, and it produces a broader definition of nonresponder than was used in the study. The trial required subjects to have at least a 16 on a particular measurement of depression symptoms, the HAM-D. According to the story, you\u2019d think a nonresponder would be anybody for whom antidepressants didn\u2019t eliminate symptoms (i.e., those with \u201cnormal\u201d HAM-D scores). But that wasn\u2019t the case. Antidepressants may have reduced their symptoms and they could still be nonresponders.\nThe story\u2019s definition of nonresponder is broader than what most clinicians or researchers woul duse; the standard is two or more failed trials. ", "answer": 0}, {"article": "For more about blood pressure drugs, visit the American Heart Association.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\nAlthough ACE inhibitors were developed 10 years earlier, both types of drugs showed similar effects in the analysis, challenging previous findings that suggest ACE inhibitors have greater benefits.\nHowever, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\nScientists at the NYU Langone Medical Center in New York City said their findings settle a longstanding debate about which of two types blood-pressure lowering medications studied are better.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story does not appear to commit disease-mongering.", "answer": 1}, {"article": "\u2022 None 6 things you can do right now to help prevent the flu \n\n\n\nThe drug uses a different approach to fight the flu than other medications.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\nIn a clinical trial, a single dose of the drug made by the pharmaceutical company eliminated the virus from people's bodies in a median time of 24 hours, The Wall Street Journal reported.\nJapanese drug regulators could approve the drug for use in Japan by early March, the Journal reported.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "To place an electronic embedded link to this study in your story: This link will be live at the embargo time: http://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2016.4219\n\nIn a study published online by JAMA Surgery, Daniel E. Hall, M.D., M.Div., M.H.Sc., of the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, and colleagues examined the effect of a Frailty Screening Initiative (FSI) on death and complications by comparing the surgical outcomes of patients treated before and after implementation of the FSI.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\nIt also suggests the potential to improve postoperative survival among the frail through systematic administrative screening, review, and optimization of perioperative plans.\nThis study included 9,153 patients (average age, 60 years) from a Veterans Affairs medical center who presented for major, elective, noncardiac surgery.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No obvious disease mongering in this release.", "answer": 1}, {"article": "Dr. Christopher B. Granger, the study\u2019s lead author and a professor of medicine at Duke University, said, \u201cI think this is a profound trial result that will have a major impact on the practice and management of patients with atrial fibrillation.\nThe first new drug, Pradaxa, from the German drug maker Boehringer Ingelheim, was introduced in the United States last fall.\nThe companies\u2019 stock soared after they released a brief statement about the stroke and bleeding benefits in June.\nIts New York-based makers are marketing powerhouses with the top two best-selling drugs in the world, Lipitor from Pfizer and Plavix from Bristol-Myers Squibb.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering.", "answer": 1}, {"article": "Attention, memory, and language improved.\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\nThe researchers stress that research in this area is important due to the expected extensive population aging over the next 20-30 years.\nThey envision that the utilization of a dietary pattern, such as the MedDiet, will be an essential tool to maintain quality of life and reduce the potential social and economic burdens of manifested cognitive declines like dementia.\nTwo of the included studies focused on younger adults and they both found improvements in cognition using computerized assessments.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The issues identified in this study are real ones for all individuals, particularly older ones. This is an important population health problem.", "answer": 1}, {"article": "\"The mounting evidence of caffeine consumption as a potentially protective factor against cognitive impairment is exciting given that caffeine is also an easily modifiable dietary factor with very few contraindications,\" said Ira Driscoll, PhD, the study's lead author and a professor of psychology at the University of Wisconsin-Milwaukee.\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\nIntake was estimated from questions about coffee, tea, and cola beverage intake, including frequency and serving size.\nDriscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\nThe researchers adjusted for risk factors such as hormone therapy, age, race, education, body mass index, sleep quality, depression, hypertension, prior cardiovascular disease, diabetes, smoking, and alcohol consumption.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "Autistic children are prone to seizures.\nLupron therapy grew from the mercury camp.\nThe drug is not approved for children \u2013 except a rare few with premature puberty \u2013 because it can impair bone development crucial to growth, said Dr. Gary Berkovitz, chief of pediatric endocrinology at the University of Miami medical school.\nLupron critics said autism parents may not understand the dangers.\nGeier's promotional materials said he has treated hundreds of children with Lupron and has launched nine ASD Centers in eight states.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in this story. ", "answer": 1}, {"article": "McIntyre points out that the bowel communicates with the brain through other pathways as well, including the metabolic and nervous systems.\nFor the new research, scientists from McMaster University in Canada recruited 44 adults with IBS as well as mild to moderate anxiety or depression.\nMost previous research on this topic has been on healthy people without mood disorders.\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\nThe probiotics were manufactured and provided by Nestle, which also funded the study.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story commit disease-mongering?", "explanation": "The story mentions mortality from pneumonia infections in adults over 65 and notes that death from pneumonia is younger people\u2013even smokers\u2013 is relatively rare.\u00a0\n\u00a0", "answer": 1}, {"article": "\"I could ride a bike!\nThere were other things the 12-year-old boy said he would do if he had two hands.\nIn truth, she had been more concerned about getting him therapy for his autism-related delays -- the limb difference was secondary.\nThey gave it to Alex for free.\nHe was wrapped in the joy of leading and advising students on how to help children like himself,\" she wrote in her iReport.\n", "question": "Does the story commit disease-mongering?", "explanation": "We will give the story a passing mark on this criterion, because it obviously applies only to people who do not have two arms. However, while the story did mention that 3D printers might be able to help provide prosthetic arms to people around the world who do not have access to conventional prosthetic arms, the story would have been better if it provided some explanation of why the patients it profiled would choose a 3D printed arm over any of the other prosthetic arms currently available.", "answer": 1}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nAnd in the new study, patients had less bleeding after stent installation.\nBut there's a problem with Plavix, and with a newer, stronger drug in the same class called Effient.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nSuch patients need anticlotting drugs because blood clots can be a deadly complication of getting a stent.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story indicated that the drug reported on was needed because \u2018blood clots can be a deadly complication of getting a stent\u2019. \u00a0While this is a true statement, it would be more informative to provide some context about how commonly blood clots occur after a person receives a stent. This information would help readers evaluate the importance of a medicine to prevent this from occurring. Nonetheless, we\u2019ll give the story the benefit of the doubt on this. \n", "answer": 1}, {"article": "Statin use may also lead to:\n\u2022 Decreased fibrosis (hardening or scarring of tissue),\n\u2022 Less development of fatty liver,\n\u2022 Slowed or halted spread of hepatitis C virus,\n\u2022 Improvement of portal hypertension (high blood pressure in the liver\u2019s blood vessels),\n\u2022 Destruction of existing liver tumor cells, and\n\u2022 Reduced risk of developing liver cancer.\nNOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209.\nThe article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nThe Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Chronic liver disease is serious and there is no evidence of disease mongering here. Some context about the disease would have been useful for readers.", "answer": 2}, {"article": "Necator americanus, the New World hookworm, is as long and thin as a vermicelli noodle.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\nIt was important that the participants be adults, because even relatively benign parasites can cause serious problems for children, pregnant women and others.\nThe doctor wanted to know whether there might be a connection between the dramatic success of deworming programs around the world and the rise of immune system problems like asthma and celiac disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not engage in disease mongering.", "answer": 1}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\n\"Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer,\" said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy.\nDr. Courtney Vito, a breast oncologic surgeon at the City of Hope Comprehensive Cancer Center in Duarte, Calif., was pleased that a serious issue in breast cancer treatment is getting a closer look.\nThose in the acupuncture group also seemed to have a generally higher overall quality of life in terms of both physical and mental health, with no serious side effects, the study authors said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here, as hot flashes associated with breast cancer treatments can negatively impact a woman\u2019s quality of life, and treatment decisions.", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n \nThe story points out that the drug has been tested only in patients with advanced disease who have tried other treatments. However, the story expands the definition of who stands to benefit by raising hopes that future studies will show effectiveness in patients with less advanced disease, even though such trials have yet to begin. Furthermore, extending these new treatments to earlier-stage disease is  problematic given the known risks for already overtreating many of these  patients.  The final quote that sequentially using the various new  medications could further extend life is troubling because there is no  evidence for this strategy\u2013which could also be very expensive. That quote could have been challenged. \n The statement that prostate cancer is second only to lung cancer as a killer of men creates a troubling comparison that obscures that fact that while most lung cancer patients die of their disease within a couple of years of diagnosis, most men diagnosed with prostate cancer ultimately die of something else after many years of life.", "answer": 0}, {"article": "\u201cTaking care of your vision is important in order to maintain good cognitive function,\u201d she said in a telephone interview.\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\nPoor eyesight and weakening mental function are common in older people and related to one another, but the question of whether vision influences cognition, or vice versa, has not been clear, the study team writes in JAMA Ophthalmology.\nOver the course of the study, average visual decline was roughly equivalent to losing the ability to read one line of an eye chart.\n", "question": "Does the story commit disease-mongering?", "explanation": "Both cognitive decline and vision loss accompany aging.\u00a0 Neither is necessarily lethal, but seeking to learn if they are related would be beneficial.\u00a0 An invited commentary that accompanied the report of this research in the Journal of the American Medical Association Ophthalmology describes a number of studies exploring this relationship in recent years,", "answer": 1}, {"article": "The study, conducted in conjunction with the University of Washington, involved 56 men who were assigned to receive one of three types of gels: one gel containing both testosterone plus a gel containing one of two doses of the synthetic progestin; or a gel containing testosterone on its own plus a \"placebo\" gel with no progestin.\nA new formulation currently being developed that contains half the amount of testosterone might decrease or eliminate that problem, Wang speculated.\nAnother question is how reversible this would be in terms of restoring sperm counts, Alukal said.\nThe combination contraceptive needs to undergo further testing before it is commercially available.\nBecause the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story commit disease-mongering?", "explanation": "Providing alternative contraception options for men is an important issue, as the story suggests.", "answer": 1}, {"article": "For example, blood pressure (BP), not only tends to increase but as well become more irregular.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\nMoreover, the higher the mean systolic BP was during the first week, the more it dropped on the second week of melatonin administration.\nMelatonin also decreased the overall variability in BP.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release is correct to note that circadian rhythms in the elderly get disrupted and can make getting a good night\u2019s sleep more challenging. But should we regard this process as an illness requiring treatment? Those with hypertension should certainly care, but it is not clear that waking up more often during a night qualifies as a medical problem for many older individuals.\nWe found this quote a bit troubling: \u201cThe older we get, the more likely our circadian rhythms are disrupted. For example, blood pressure (BP), not only tends to increase but as well become more irregular. Luckily, as we show in our research, melatonin helps to ameliorate both trends.\u201d\u00a0\u00a0This \u2018process\u2019 of blood pressure variability may in fact be normal physiology and is not necessarily the culprit for poor sleep.", "answer": 0}, {"article": "\"That's about 20 pounds,\" Smith said.\nA potential player in fighting the obesity epidemic, lorcaserin is a new type of weight-loss drug that works by acting on serotonin, a chemical associated with feelings of well-being and feeling full, and does not appear to increase blood pressure or cause any other heart problems, according to the researchers, whose work was sponsored by the drug manufacturer.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\nIt helped patients in clinical trials lose as much as 13 percent to 15 percent of body weight.\nAfter one year, 47.5 percent of those taking lorcaserin had lost 5 percent or more of their body weight.\n", "question": "Does the story commit disease-mongering?", "explanation": "The second sentence begins, \"A potential player in fighting the obesity epidemic.\" That is the sole reference to the problem of obesity, and, although it contributes to the framing of\u00a0obesity as a disease that needs medication versus a risk factor for disease that can be altered with lifestyle changes, it doesn\u2019t quite register as disease mongering. So we judge this\u00a0 to be satisfactory. ", "answer": 1}, {"article": "Asthma patients suffer fewer attacks and need fewer hospital visits.\nSince then, about 650 patients across the country have had the procedure.\n\u201cIt\u2019s not going to get rid of asthma, but it is going to reduce symptoms and hospitalizations and make patients more functional in their daily life.\u201d For now, the procedure is only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications, said Dr. Kyle Hogarth, an assistant professor of medicine at the University of Chicago who was involved in clinical studies of the treatment.\nBut several five-year studies showed no long-term safety issues.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story notes that the procedure\u00a0\u201cis only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications.\u201d", "answer": 1}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThe Lincoln team has successfully synthesized new simplified versions of teixobactin which harness the same powerful antibiotic effects in a way that could be produced on a commercial scale.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nScientists working to develop a 'game-changing' new antibiotic have made a significant advance towards creating commercially viable drug treatments by producing two simplified synthetic versions of the substance which are just as potent at killing superbugs like MRSA as its natural form.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t disease monger. There is no doubt that antibiotic resistant infections are a widespread and growing threat.", "answer": 1}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story commit disease-mongering?", "explanation": "There is no obvious disease-mongering. The story accurate represents the prevalence and seriousness of head and neck cancer.", "answer": 1}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no real mongering here.\nAs a side note, the article cites statistics regarding the disease in general. Since the study only enrolled a subset of babies with this disease, it would be interesting to know how representative its sample was.", "answer": 1}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\nAgatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\nA calcium score would answer that question, she says.\n(Agatston does not make any money from the coronary calcium scan.)\nAgatston thinks the coronary calcium scan should be routinely scheduled at age 50, like a colonoscopy, or earlier for people with family histories of heart disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story exemplifies disease-mongering by highlighting threats of terrible consequences and wildly exaggerating the number of people likely to benefit from these scans. With statements like, \u201cunless you do imaging, you are really playing Russian roulette with your life\u201d and \u201cAgatson thinks that the coronary artery calcium scan should be routinely scheduled at age 50\u2026\u201d provide the uninitiated reader with the impression that everyone needs one of these tests.\u00a0 While the comments of Dr. Michos modify the unabashed enthusiasm, the overall tenor is over the edge.", "answer": 0}, {"article": "Insulin may have a relationship with cancer.\n\"The evidence in diabetic humans is very convincing and very strong,\" added Dr. Phillip Dennis, a senior investigator with the U.S. National Cancer Institute and senior author on the lung cancer paper.\nOthers believed that the finding might influence the choice of drugs in people with diabetes.\nThis adds credence to the idea that metformin's value is in its ability to lower overall insulin levels in the body, Cantley said.\nAnd when the drug was administered by injection, the improvement seen was 73 percent.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in this story. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "There is persuasive evidence linking exposure to the sun\u2019s ultraviolet rays to melanoma, a formidable and sometimes fatal skin cancer, as well as to skin wrinkling and age spots, in certain individuals. The article mentions this link once, but does not dwell on it.", "answer": 1}, {"article": "Lauren Dunn is a medical producer for NBC News; Linda Carroll is a contributor for NBCNews.com\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\nAlso, Hamilton notes, the implants aren\u2019t a \u201cbe all end all.\nAnd now she\u2019s able to read without the aid of glasses.\nWithout the glasses, she can\u2019t read anything.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering, though including everyone older than\u00a035 years old in the \u201caging\u201d category may have been overkill.", "answer": 1}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nThe study included men and women.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering. We also applaud the context in behavioral and financial realities that is part of the story.", "answer": 1}, {"article": "Lobular breast cancer forms in the milk glands.\nThe use of fish oil was linked to lower risk of invasive ductal breast cancer.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\nMany people currently take fish oil supplements to decrease their risk for heart disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering. ", "answer": 1}, {"article": "The stool was more solid, the diarrhea goes away, and the bloating is much less.\"\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\nExisting treatment options -- diet and lifestyle modification, psychological therapy, and other drugs -- do not help all people with the condition.\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease-mongering and presented the information about the disease in a straightforward way. \u201cThe study looked only at those IBS patients with the non-constipation form, he tells WebMD. For those with this type of IBS, symptoms can include abdominal pain, bloating, and changes in bowel function such as diarrhea.\u00a0IBS is considered a functional gastrointestinal disorder without a known physiologic cause, with the symptoms recurring and often worsened by stress. Existing treatment options \u2014 diet and lifestyle modification, psychological therapy, and other drugs \u2014 do not help all people with the condition.\u201d", "answer": 1}, {"article": "No one knows why some women have this capability and others do not, but for those who lack it the Inovio vaccine is \"giving our immune system a little boost,\" Kim said.\nGiven those drawbacks, it\u2019s not appropriate to draw too many conclusions from this study, says Dr. Diane Harper, a prominent HPV researcher at the University of Missouri \u2013 Kansas City\u2019s School of Medicine.\nThe vaccine consists of three injections in the arm over three months, Kim said.\nThis happens in anywhere from 10% to 25% of women infected with HPV, Kim said.\nThe vaccine trains T-cells in the body to go after cervical cells with potentially cancerous genes embedded in them.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not appear to commit disease mongering.", "answer": 1}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nObviously, the process will have to be refined and optimized before it's actually used for treatment.\nThe precision of the process is crucial to limiting side effects, the researchers said.\nThe experiment proceeded just as planned, as biopsies later showed.\nBut the work that nabbed the prize was done in worms -- a far cry from humans.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable because no diseases were discussed in any detail. ", "answer": 2}, {"article": ".\nThe study is titled \"Dry Needling Versus Cortisone Injection in the Treatment of Greater Trochanteric Pain Syndrome: A Noninferiority Randomized Clinical Trial.\"\nCo-authors on the paper are Bryce C. Allen, MD, and Yolanda Munoz Maldonado, PhD, also with Baylor Scott & White Health.\n\"Evidence for dry needling of the hip in lieu of steroid injection is in its infancy,\" acknowledges lead author Kindyle L. Brennan, PT, PhD, with Baylor Scott & White Health.\nDr. Brennan cautions that while this study uses a larger sample than most, further studies are warranted.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. Hip dysfunction is very common, and the news release doesn\u2019t appear to overstate that. It says GTPS \u201cis estimated to affect 10% to 25% of the general population. This kind of hip pain has been reported to be more common in women and in patients with coexisting low back pain, osteoarthritis, Iliotibial band tenderness, and obesity.\u201d", "answer": 1}, {"article": ".\n\"These findings are the first example of a precision therapy that is uniquely effective in a subgroup of patients with treatment-resistant COPD.\"\nThe METREO results narrowly missed statistical significance.\nThe 300-milligram dose did not provide an advantage over the lower dose.\nThe first trial, termed METREX, was conducted at 117 sites in 15 countries from 2014 to 2017.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nTheir results showed that magnesium is safe and effective and comparable to prescription SSRI treatments in effectiveness.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\n\"The results are very encouraging, given the great need for additional treatment options for depression, and our finding that magnesium supplementation provides a safe, fast and inexpensive approach to controlling depressive symptoms.\"\nNew clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease-mongering here. The news release called depression an \u201cenormous disease burden.\u201d This is true\u2014depression is a huge problem that affects millions of people. The World Health Organization says more than 300 million people worldwide suffer from depression.", "answer": 1}, {"article": "\"We always assume there's luxury,\" Wright said.\nAccording to Dr. Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York, and Long Island Jewish Medical Center in New Hyde Park, New York, the importance of this study is that it brings to light that there are new biomarker tests that can delineate between these neurological diseases.\nThough other symptoms will show up eventually and help in diagnosing the patient, in the meantime, the patient will be receiving the wrong medicines.\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\nHe also believes the test will be used by specialists for Parkinson's patients who \"do not exhibit a very typical symptomatology\" or do not respond as expected to treatment.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not disease monger, and it did a nice job describing how common these atypical diseases are, compared to Parkinson\u2019s disease.", "answer": 1}, {"article": "Brain scans and spinal taps are helpful but they're not certain.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nCurrently, an early Alzheimer's diagnosis requires complex brain scans.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the problem and prevalence of Alzheimer\u2019s disease.\u00a0 However, by repeating the mantra that an early diagnosis by a blood test is a good thing, one is led to believe that there is an intervention that may be widely applicable. (It states: \"For millions who worry their forgetfulness could be the first sign of something worse, a blood test could, in the future, provide answers.\")\u00a0 In this sense, there is disease mongering by implying many could benefit from this test when the notion of benefit is speculative at best.", "answer": 0}, {"article": "Zeitzer was on the committee that removed jet lag as a \u201cdisease\u201d from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the guide that psychiatrists use to diagnose mental illnesses.\n\u201cJet lag itself is really a nuisance syndrome as it is self-resolving,\u201d said senior author Jamie Zeitzer, assistant professor of psychiatry and behavioral sciences at the Stanford University School of Medicine in California.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\nAs for frequent flyers trying this themselves, it is \u201cfar too early \u2013 neither the methodology is available outside research, nor any guidance about safety, nor tests of simulated jet lag in an appropriate \u2018realistic\u2019 protocol,\u201d Wirz-Justice told Reuters Health by email.\nIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality, he added.\n", "question": "Does the story commit disease-mongering?", "explanation": "The report included this helpful phrase to indicate that this isn\u2019t a \u2018real\u2019 disease: \u201c\u2019Jet lag itself is really a nuisance syndrome as it is self-resolving,\u2019 said senior author Jamie Zeitzer, assistant professor of psychiatry and behavioral sciences at the Stanford University School of Medicine in California.\u201d", "answer": 1}, {"article": "March 29, 2011 -- A minimally invasive procedure that cuts off the blood supply to an enlarged prostate may help when medications fail, and it appears to provide good symptom control without sexual dysfunction, a new study shows.\nThe authors report that the dead tissue required surgical removal.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\nThe procedure involves using a tiny catheter that is threaded through arteries near the groin to reach the vessels that supply the prostate with blood.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story provided the reader with the fact that benign hyperplasia affects 19 million American men without any additional context about the men affected. \u00a0It would have been useful, for example to explain that this was a chronic condition that becomes more common as men age; some men find their symptoms severe enough to seek treatment; others are less bothered by the condition. BPH is not likely to cause serious complications. There are men who choose to watch and wait, and who bypass treatment entirely. You\u2019d never get that notion from this story.", "answer": 0}, {"article": "Sorry. The page you requested is not available", "question": "Does the story commit disease-mongering?", "explanation": "The article does nothing to exaggerate the severity or consequences of MS.", "answer": 1}, {"article": "It may also improve vision in those with mild myopia (nearsightedness).\nScientists don\u2019t know exactly how perceptual learning relieves presbyopia, but they have some clues based on how our brain processes visual information.\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nAfter training, the older adults\u2019 ability to see low-contrast images improved to the level that the college-age ones had before training.\n", "question": "Does the story commit disease-mongering?", "explanation": "Comments about bifocal-wearing contributing to accidents are arguably on the line of disease mongering. In the linked study cited to support this point, there was no statistically significant difference in falls between groups that had bifocals or who wore single lens glasses. But, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here; moderate to severe depression is a real and prevalent disorder and danger. We also thought it was wise how the story included a patient narrative with unclear results\u2013she\u2019s feeling better, but not 100%. That is a very powerful way to explain that this new tool isn\u2019t a silver bullet.", "answer": 1}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nThe pill, called Truvada, is already on the market for treating HIV infections.\nThat'll help avoid creating viruses resistant to the drug when patients miss doses.\nThat doesn't tell the whole story.\nNow health officials are warning doctors that preventing the disease will take more than just writing a prescription.\n", "question": "Does the story commit disease-mongering?", "explanation": "NO disease-mongering here.", "answer": 1}, {"article": "\u2022 Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;\n\u2022 Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room.\nThe faculty of almost 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments.\nUTSW is currently the only accredited site in Texas at which this spacer gel can be used.\nThe SBRT study for prostate cancer was supported by a grant from the U.S. Department of Defense.\n\"SBRT is both more convenient and has increased potency.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in overt disease mongering.", "answer": 1}, {"article": "A Buck Institute press release on the study stated: \"None of the patients were able to stick to the entire protocol.\nBredesen noted, too, that the MEND protocol was suitable for patients in the early stages of Alzheimer's.\nBut even if MEND is effective, the program is complex and difficult to follow.\nJames E. Galvin, M.D., M.P.H., a professor of clinical biomedical science at FAU's Charles E. Schmidt College of Medicine and a professor in the Christine E. Lynn College of Nursing, who was not involved in the study, agreed that personalized approaches such as the MEND protocol are the types of approaches needed for this disease going forward.\nBredesen said that to simplify the program, they are connecting patients with health coaches.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no exaggeration of the seriousness of Alzheimer\u2019s. However, the story should have been more careful in its wording. Calling a cure for Alzheimer\u2019s \u201cthe holy grail in disease research\u201d isn\u2019t accurate. There are plenty of horrible illnesses for which cures are being actively sought.", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not overplay the import or incidence or cognitive decline.", "answer": 1}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nThis discovery is akin to the revolutionary breakthrough made last century that confirmed folic acid supplementation can prevent spina bifida and other neural tube defects in babies.\nThis breakthrough, led by Professor Sally Dunwoodie from the Victor Chang Institute, has identified a cause of recurrent miscarriages as well as heart, spinal, kidney and cleft palate problems in newborn babies.\n\u201cJust like we now use folate to prevent spina bifida, Professor Dunwoodie\u2019s research suggests that it is probably best for women to start taking vitamin B3 very early on, even before they become pregnant.\nThe landmark study found that a deficiency in a vital molecule, known as NAD, can prevent a baby\u2019s organs from developing correctly in the womb.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering. The study rightly points out that miscarriages and birth defects affect millions of families worldwide.\u00a0", "answer": 1}, {"article": "Sept. 26, 2017.\nNo patient died during the trial.\nThe research, published Sept. 26 in the Journal of the American Medical Association, reports results from the clinical trial known as GIFT (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis).\nGIFT showed that precision-medicine based on clinical factors and three genes improves the safety of initiating warfarin therapy.\"\nUnlike prior studies, GIFT took into account genetic variants in three genes for 11 days of warfarin therapy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\nAhlquist noted that the test still needs to be refined.\nSavings over time on a more accurate test done fewer times could justify the higher cost of the Cologuard test, Ahlquist said.\nAccording to Ahlquist, Cologuard is the first noninvasive test to detect pre-cancerous polyps, he added.\nPolyps this size are considered pre-cancers and most likely to progress to cancer, Ahlquist said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\"There's no magic in a liter-and-a-half,\" he said.\nWhether the advice would benefit women with normal urine output, however, is unclear, Wessells noted.\nDr. Susan Bleasdale, medical director of infection control at the University of Illinois at Chicago, said the study \"may be a game changer\" for antibiotic \"stewardship\" programs aimed at reducing inappropriate antibiotic use.\nThe study, conducted in Bulgaria, involved 140 healthy premenopausal women who had at least three UTIs in the past year.\nYoung women plagued by UTIs who drank an additional 6 cups of water each day were nearly half -- 48 percent -- as likely as a control group to have another infection, the study showed.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not disease-monger and it discussed the prevalence of UTIs and why they affect women more often. However, we think it could have dialed back some of the predictions that this could lead to the end of antibiotic use for UTIs.", "answer": 1}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story commit disease-mongering?", "explanation": "The story repeats the commonly cited CDC statistics on people who are obese and overweight. It does not engage in disease-mongering.", "answer": 1}, {"article": "Other scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nEach variation alone would have only a tiny effect on health.\nBut specialists in heart disease and genetics who weren't involved with the research called the new findings exciting because of their scope.\nAn unhealthy lifestyle could overwhelm the protection of good genes.\nIt doesn't require the most sophisticated type of genetic testing.\n", "question": "Does the story commit disease-mongering?", "explanation": "No apparent disease mongering here.", "answer": 1}, {"article": "In the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n\"This study adds to the literature on vaginal laser therapy for GSM.\n\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\nStudy results are published in the article \"Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results.\"\nThe results of this small, retrospective, non-sham-controlled study demonstrated that this type of laser surgery was particularly effective in reducing the intensity of dyspareunia (painful sex) and dryness.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release tells us that \u201cpainful sex, dryness, itching/burning, urinary frequency, and incontinence\u201d are symptoms and signs associated with menopause. We\u2019re also told that \u201ccollectively\u201d these represent genitourinary syndrome of menopause (GSM) which the gynecologic literature\u00a0variably describes as either a \u201ccondition\u201d or a \u201cconstellation of symptoms\u201d associated with low estrogen levels in women. (See this helpful essay from Harvard Women\u2019s Health Watch.)\nSome readers might be left wondering: \u201cSo is GSM a disease? Do I need to have all the symptoms to qualify? Aren\u2019t many of these symptoms part of \u2018normal\u2019 menopause? Or, is having such symptoms abnormal and should therefore be treated?\u201d\nWe wish the news release had made it clear that these symptoms can represent normal aspects of aging that many women choose to manage with non-pharmacologic and non-surgical approaches.\nWe\u2019ll give this the benefit of the doubt and rate this satisfactory since it\u2019s debatable whether or not this news release disease mongers.", "answer": 1}, {"article": "TMS works by producing an electrical current that can pass through the skull and into the target area of the brain.\nIn a second phase of the study, all patients were given the real TMS treatment.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\nGeorge said he and his colleagues would like to study whether giving people TMS intermittently instead of putting them on antidepressants would produce equally durable effects.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story doesn\u2019t resort to disease-mongering.", "answer": 1}, {"article": "Prostate cancer becomes more common as men age \u2014 autopsies of elderly men find that most had prostate cancer, whether they knew it or not.\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\nStill, he said the new test could help patients if it was used with caution.\n\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\nThe next step was to ask whether those variants really could predict who had prostate cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "A couple of the quotes border on disease-mongering when discussing the prospect of earlier prostate cancer screening \u2013 even in men in their 30s.. However, the story attempted to provide some context with expert comment questioning the wisdom in this approach.", "answer": 1}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story commit disease-mongering?", "explanation": "We think this article does engage in disease-mongering. The statistical sidebar cites some grim outcomes of head trauma. These numbers cloud the point of the story, which is about undiagnosed or slow-to-diagnose cases. How many of the\u00a03 million people who need long-term care\u00a0and\u00a0the 52,000 who died had\u00a0undiagnosed\u00a0severe brain injuries? How many died on contact?\u00a0How often\u00a0does the current diagnostic approach fail?\u00a0In other words,\u00a0who exactly might this new technique benefit?\u00a0While perhaps no one knows those answers, we think the overly general sidebar inflates the expectations balloon too much.\nAnother point that was easy to miss: the tests in humans measured UHC-L1 in spinal fluid. That requires a spinal tap. While it\u2019s something one might consider in the first scenario, it\u2019s unlikely to be practical for the second. One would expect that the test characteristics of a CSF level are different from a blood level.\u00a0", "answer": 0}, {"article": "\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\nDoctors currently use a test known as amniocentesis to check whether a baby is likely to be born with Down\u2019s.\nPatsalis\u2019 method takes advantage of differences in the DNA methylation patterns \u2014 which are important to control levels of genes \u2014 between mother and fetus.\nIn a study in the Nature Medicine journal researchers from Cyprus said a trial on 40 pregnancies using the test, which involves analyzing the woman\u2019s blood to detect DNA differences between the mother and the fetus, showed it accurately predicted which fetuses were at risk of developing the syndrome.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nThe French research team worked with 26 patients who received active TMS treatment, and 33 as a control group, who received sham (placebo) treatment.\nFor the first time, scientists have precisely identified and targeted an area of the brain which is involved in \"hearing voices\", experienced by many patients with schizophrenia.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here, and we appreciated the discussion of prevalence of schizophrenia.", "answer": 1}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\nAnd although checkpoint inhibitors are off the shelf, with every patient getting the same drug, CAR T-cell therapy is customized to an individual.\nSuch results are why the treatment is on track to become the first gene therapy approved by the Food and Drug Administration.\nThe article that appeared in the New England Journal of Medicine in August 2011 created a \u201cfirestorm,\u201d June said \u2014 one that brought them new resources.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s really no disease mongering here, though there is one point that we\u2019d like to single out. The story states that the CAR T-cell treatment \u201cinitially would be available only for the small number of children and young adults whose leukemia does not respond to standard care. Those patients typically have a grim prognosis\u201d [emphasis added]. What does it mean to \u201ctypically have a grim prognosis\u201d? It\u2019s a fine turn of phrase, but it doesn\u2019t actually convey much information \u2014 and it\u2019s scary. In a case like this, it would likely be better to let the numbers speak for themselves. Or, if a story does include this sort of language, to back it up with some numbers.", "answer": 1}, {"article": "For more information, visit us at allinahealth.org, Facebook, Twitter, YouTube or Healthy Set Go.\nPhysicians at the Virginia Piper Cancer Institute wanted to know if surgical procedures to test the lymph nodes for cancer were always necessary.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nHow to treat patients who have microinvasive breast cancer - tumors that are 1 mm or less in size (the thickness of a dime) -- is somewhat controversial.\nThe Virginia Piper Cancer Institute\u00ae, part of Allina Health, provides comprehensive care through all aspects of cancer prevention, early detection and treatment to help individuals maintain quality of life and find ways to live with and beyond cancer.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering. The management of microinvasive breast cancer \u2014 which includes assessing how it spreads \u2014 remains a common surgical dilemma.", "answer": 1}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\nKing and her team are the first to show that a modest increase in dietary zinc reduces oxidative stress and damage to DNA.\n\"These results present a new strategy for measuring the impact of zinc on health and reinforce the evidence that food-based interventions can improve micronutrient deficiencies worldwide.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no explicit disease mongering in this news release. However, the reference to \u201cexcessive DNA damage\u201d from insufficient zinc consumption and the statement that \u201cZinc also helps limit inflammation and oxidative stress in our body, which are associated with the onset of chronic cardiovascular diseases and cancers\u201d could plant fear in some readers\u2019 minds.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story commit disease-mongering?", "explanation": "This is one story that does not commit disease-mongering of toenail fungus.\u00a0 It includes a discussion of the mild end of the spectrum \u2013 in which nail fungus is \u201cmerely a cosmetic problem.\u201d", "answer": 1}, {"article": "\u201cI\u2019ve had patients who wouldn\u2019t dream of not being treated,\u201d Dr. Berchuck said.\nMoreover, the extra chemotherapy seemed to worsen the quality of life.\nDoctors are convinced that if the initial diagnosis can be made early, which is very difficult, the cancer can be treated by surgery.\nThis new study does not refer to initial diagnosis of ovarian cancer, only to a relapse.\nThe finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of Ovarian Cancer.", "answer": 1}, {"article": "WINSTON-SALEM, N.C. - Aug. 17, 2015 - Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury.\nSixty-eight study participants received either a monthly vitamin D supplement of 100,000 international units or placebo delivered with their MOW meal.\nThe Wake Forest Baptist team currently is conducting a clinical trial to try to determine how vitamin D affects risk factors for falls such as balance and muscle strength and power.\nFunding for the study was provided by the Wake Forest Translational Science Institute and Center for Integrative Medicine and the Claude Pepper Older Americans Independence Center of Wake Forest Baptist.\n\"Falls in homebound older people often lead to disability and placement in a nursing home,\" said Denise Houston, Ph.D., R.D., associate professor of gerontology and geriatric medicine at Wake Forest Baptist and lead author of the study.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release did not appear to exaggerate the severity of the problem.", "answer": 1}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 0}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nResponse by others in the field was positive but not effusive.\nA team of researchers from the National Cancer Institute reported yesterday that they have successfully treated two cancer patients using gene therapy, the introduction of genes into the human body for medical purposes.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\n", "question": "Does the story commit disease-mongering?", "explanation": "Cancer has a scary connotation for most people. This story failed to inform the viewer about how common death from melanoma was. While they presented an estimate for the number of Americans that will be diagnosed with melanoma in 2006 (~ 60,000) there was no mention that it is estimated that there would be <8,000 deaths attributable to melanoma. This information is helpful for recognizing that melanoma is much less common and deadly than a number of other diseases. ", "answer": 0}, {"article": "Eating more fiber during adolescence was linked to a 16 percent lower risk of breast cancer overall, and a 24 percent lower risk of breast cancer before menopause.\nEating more fruits and vegetables was especially beneficial, the researchers said.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\n\"Having the recommended 25 to 30 grams of fiber daily would decrease the risk by 30 percent and potentially even greater with higher fiber intake,\" Farvid said.\nShe said that recently more evidence has come to light suggesting a relationship between dietary fiber and breast cancer risk, and that eating more fiber would be a simple way to reduce risk.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "6 Kowdley KV, et al.\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\nThe study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, also showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It notes the prevalence of hepatitis C among children, which \u201cvaries from 0.05%-0.36% in the United States and Europe and up to 1.8%-5.8% in some developing countries.\u201d It would have been even better with specific numbers.", "answer": 1}, {"article": "The results were published in Wednesday\u2019s edition of the Journal of the American Medical Assn.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\nThe researchers also found that the popularity of folic acid supplements rose as time went on.\nBut not all mothers were equally likely to take folic acid supplements.\nThese children were more likely to be born to women who did not take folic acid.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story mentions the puzzlement about why rates of autism appear to be rising in the US, thus giving readers a sense of how much remains unknown about potential causes or responses.", "answer": 1}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\nThe study is published in the New England Journal of Medicine.\nBut as successful as the drug appears to be for some patients, it may come with a significant risk.\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of psoriasis here.", "answer": 1}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nFurther study is necessary to clarify possible mechanisms through which walking and vigorous activity might affect time-to-pregnancy.\"\nWhitcomb says another way in which this study is distinct from other work in this area has to do with who was included in the study.\nThe EAGeR trial focused on women with a history of one or two prior pregnancy losses.\nModerate activity, sitting and other activity categories were not associated with fecundability overall or in BMI-stratified analyses, they add.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "During the process, blood is drawn from the patient and then injected back into the pained joint.\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nIt's a non-drug, non-surgical treatment derived from your own blood.\nThe European-based process was the inspiration for Dr. Barreto of Oklahoma City, Oklahoma to work on developing a stronger, more effective, and more cost-efficient version in the United States.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This was a tough call and we gave them the benefit of the doubt on this criteria. Although the release doesn\u2019t disease monger about joint pain, without a clear indication of who should get this injection, it may imply that anyone with joint pain could consider this treatment. And that\u2019s not the case.", "answer": 1}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nGreatest changes were seen in the ability of patients to perform Sports and with improvement in healthful daily activity.\nA statistically significant improvement for both groups was noted for the final follow-up for IKDC and all five KOOS sub-scores.\nHowever, seeing this type of success allows sports medicine physicians another option in older patients and serves as a predictable biologic joint preservation technique,\" said Crawford.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. However, the story also doesn\u2019t provide any context on what this procedure is supposed to treat or the impact of that condition. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Their average age was 69.\nThere needs to be a large head-to-head trial between Forteo and abaloparatide, she said, to really see which drug is better.\nAn editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment.\nAbaloparatide and Forteo are synthetic peptides that help grow and strengthen bone, Miller said.\nThere were no differences among the groups in other serious side effects, such as nausea and heart palpations, Miller said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story shares the fact that\n\u201cA study based on 2010 U.S. Census data estimated that more than 3 million women between the ages of 50 and 69 have osteoporosis. A 60-year-old woman has a 44 percent lifetime risk of fracture due to low bone density.\u201d\nAn explanation of the term \u201clifetime risk\u201d would be helpful to the reader. (In this setting, it means\u00a0the probability of experiencing a fracture during the remaining years of life. In fact, the figure reported is really a \u201cresidual lifetime risk.\u201d)\nNow for a slight tangent: It is great that the story chose to report an absolute risk here rather than a relative risk. This is a point we at HealthNewsReview.org try to hammer home. In a 2007 article in the Journal of Bone and Mineral Research, Nguyen et. al. in their article titled \u201cResidual lifetime risk of fractures in women and men\u201d had the following comment on relative versus absolute risk:\nCommunication of risk in the osteoporosis field has traditionally relied on the concept of relative risk. However, relative risk can be misleading to patients and clinicians,(42) because the interpretation of a relative risk or its change is highly dependent on the baseline risk. For instance, doubling a minor risk is still minor, but doubling a common risk is alarming. It is therefore desirable that individuals who have BMD measurements be informed about their fracture probability risk category instead of their relative scores.(4) The lifetime risk estimates from this study provide such a means for communication of risk to an individual patient.", "answer": 1}, {"article": "While prenatal testing is widely used for pregnant women at risk of having babies with chromosome disorders such as Down syndrome, new research shows certain types of tests may also reveal markers of cancer in mothers.\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\nMore testing showed she had anal cancer.\nFurther testing showed the baby was healthy.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story focuses on an individual woman\u2019s story, and provides no perspective on the rarity of her case. Although it may be an underestimate, cancer was reported in only\u00a00.008% of the samples analyzed. The story needed some acknowledgment that this is an exceedingly rare occurrence.", "answer": 0}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThe mean follow-up was 18 months for both heart failure groups and just over two years for both non-heart failure groups.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0Not applicable because there was really no discussion of heart failure incidence or seriousness. ", "answer": 2}, {"article": "I couldn't get anything done,\" Ham said.\nThen, a friend mentioned marijuana, which Maine had legalized in 1999 for chronic pain and scores of other medical conditions.\nSubstance abuse experts argue there are already approved medications.\nMany medical professionals say there's not enough evidence for them to confidently prescribe it.\nIt would also be wrong to portray marijuana as completely safe, they say, because it can also be addictive.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no obvious disease mongering in this story. Opioid addiction is real and very problematic.", "answer": 1}, {"article": "In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\nNor is it for women who have other conditions that raise their risk of preterm birth, such as high blood pressure or infection.\nAnd even for the 30,000 or so women who are eligible, 17-HP, which will be marketed as Makena, isn't a magic bullet.\nInterestingly, the drug is not new \u2014 it's just taken a long and circuitous route to approval.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of prematurity or its consequences.", "answer": 1}, {"article": "\"That helps explain the false positives,\" Audeh said.\n\"Despite poorer performance compared with women without a prior history of breast cancer, overall screening mammography was effective at detecting the majority of breast cancer in women with a [history] at an early favorable stage, with the majority of tumors being diagnosed as ductal carcinoma in situ or stage 1,\" Smith said.\n\"Screening mammography does work well in women with a history of breast cancer, so they should continue to get their annual screening mammogram,\" said Diana Miglioretti, senior investigator at Group Health Research Institute in Seattle and a co-author of the new research.\nThe interval cancer rate was 3.6 per 1,000 screenings in those with a history and 1.4 per 1,000 in those without, the investigators found.\nDr. William Audeh, medical director of the Samuel Oschin Cancer Center and the Wasserman Breast Cancer Risk Reduction Program at Cedars-Sinai Medical Center in Los Angeles, described the findings as \"not at all surprising.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The headline of this story misleads the reader by stating that \u201cMammograms May Not Be Fool-Proof at Catching Second Cancers.\u201d\u00a0 No type of screening for breast cancer is fool-proof whether it is for an initial diagnosis or for a second breast\u00a0cancer.\u00a0 Regarding the accuracy of screening mammography for an initial breast cancer diagnosis, the Komen for the Cure website states that in women age 50 and older \u201c\u2026between six and 27 percent of breast cancers may be missed by mammography alone.\u201d\u00a0 Mammography is most effective in women 50 and older.", "answer": 0}, {"article": "\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\nDr. Richard Lipton, director of the Montefiore Headache Center in New York City, described the findings as \"very dramatic.\"\nMandato stressed that no one in the study required sedation to undergo the procedure.\nThe study received no funding from private industry.\nSeven of the patients (about 6 percent) failed to get any benefit from the treatment, the investigators found.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article did not engage in disease mongering.", "answer": 1}, {"article": "WASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nMoscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\nDr. Anne Moscona of Weill Cornell Medical Center in New York and colleagues tested varying doses of the drug, also known as DAS181, in lab dishes and on cotton rats, a species accepted by scientists for testing parainfluenza.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\n", "question": "Does the story commit disease-mongering?", "explanation": "       \n \nThe story fails to note that parainfluenza virus infections do not cause serious disease in the majority of people.\u00a0In doing so, it provides an overly disconcerting  picture of the virus and its potential to cause serious illness. The failure to provide background information in combination  with the initial quote of the lead author, \u201cTherapies for parainfluenza  are urgently needed,\" qualifies as disease-mongering. \n ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "The story did a bit of disease and treatment mongering.\u00a0 Describing these medications as \u2018lifesaving pills\u2019 which people take to protect themselves \u2018against the ravages of heart disease\u2019 sets a tone that is not conducive to helping readers think objectively about the research results being reported on.", "answer": 0}, {"article": "In recent years, emergency service dispatchers have been coaching callers in hands-only CPR rather than telling them how to alternate breaths and compressions.\nBut less than a third of victims get this essential help.\nIn a major change, the American Heart Association said Monday that hands-only CPR - rapid, deep presses on the victim's chest until help arrives - works just as well as standard CPR for sudden cardiac arrest in adults.\nThe CPR guidelines had been inching toward compression-only.\nNow the heart association has given equal standing to hands-only CPR.\n", "question": "Does the story commit disease-mongering?", "explanation": "The segment does nothing to exaggerate the frequency or severity of sudden cardiac arrest. ", "answer": 1}, {"article": "\"If someone said to my husband, 'I know this has been a rough road for you, and a big impact on your sex life, but if she stays on it another five years.\nTamoxifen is the only hormonal option for women before menopause, Litton says.\nThese drugs are slightly more effective than tamoxifen, although they don't work before menopause, Litton says.\nGray noted that tamoxifen has risks.\nStudies show that only 80% of women take tamoxifen for five years, Litton says.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease-mongering.", "answer": 1}, {"article": "At the same time, we studied a small sample of patients, so our results should be interpreted with caution,\" Fried added.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\nSo it's difficult to generalize this study's results to other diseases that affect memory, she said, and the research didn't show if effects of temporary deep brain stimulation last beyond the study period.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\n\"The thing to bear in mind is that it's a first, important step,\" said Suzanne Haber, a brain researcher and professor of pharmacology and physiology at University of Rochester Medical Center in New York, who wasn't involved in the study.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate who might eventually benefit from this line of research.", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nAn immunotherapy drug has been hailed as a potential 'game changer' after being found to greatly improve survival for patients with relapsed head and neck cancer - a disease which is notoriously difficult to treat.\nThe trial was led in the UK by Professor Kevin Harrington of The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 20 research organisations from around the world.\nThis trial found that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life.\nIt was funded by Bristol Myers Squibb.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\"This is a test that doesn't just diagnose prostate cancer.\nAnd men diagnosed with prostate cancer whose PSA is rising slowly may be ideal candidates for monitoring instead of surgery or other treatment, he added.\nThe work is \"another step on the road to more sophisticated\" prostate cancer screening and treatment, Dr. Timothy Church of the University of Minnesota wrote in an editorial accompanying the work.\nA study with just 20 deaths is far too small to prove the value of PSA velocity, cautioned Dr. Durado Brooks, a prostate specialist with the American Cancer Society.\nWASHINGTON \u2014 Prostate cancer is more likely to be life-threatening if the man's PSA level rose rapidly during the years before he was diagnosed, says a new study that may help change how PSA tests are used.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article nicely describes the dilemma around whether or not to find and/or treat prostate cancer. Many prostate cancers are slow-growing and will never threaten a man's life.\u00a0 This is often lost in the enthusiasm over PSA testing.\u00a0 The article also provides some estimates of the number of men who will be diagnosed and die from prostate cancer this year, giving some framework for the relative burden of prostate cancer (or showing that despite a relatively larger number of men who will be diagnosed, a minority of them will die from the disease).\u00a0 However, the article misses an opportunity to emphasize or re-state what the numbers really mean and that they demonstrate there should be caution about widespread screening.\u00a0 ", "answer": 1}, {"article": "Nonetheless, the doctors were pleased when M.R.I.\nDr. Boockvar said microcatheters should increase the odds of success by delivering a high dose of the drug directly to where it was needed most.\nThat means a lot to me.\u201d\n\nDr. Boockvar said: \u201cAvastin may not be the best drug for this delivery technique.\nscans of the first few patients showed that the treatment seemed to erase any sign of recurring glioblastomas.\n\u201cNobody knows.\u201d\n\nIndeed, the death of the first patient was a reminder that glioblastoma can invade other parts of the brain and the spinal fluid and that the highly localized spray of Avastin might miss deadly seeds of cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article describes glioblastoma\u2019s deadliness with facts and data rather than appeals to emotion. The language is in some places dramatic but not inappropriately so. ", "answer": 1}, {"article": "\u201cWe need at least 1 \u00bd to 2 years\u2019 worth of data\u201d to make a meaningful judgment about how to proceed, Dr. Carter said.\nThis rate, known as PSA velocity, will be part of the new guidelines, which will suggest that in men with low readings, doctors consider the changes in levels over the course of three measurements.\nBut, he added, \u201cIf we biopsied every man with a PSA below 4, we\u2019d be looking at a sea of cancers that would never grow to be life threatening.\u201d\n\nThese facts and the results of a recent study by Dr. Carter, among others, indicated that rather than acting on the basis of a single PSA test, the rate of change in levels over time is a better indicator of who might have a serious cancer.\n\u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n\nThe new guidelines will lower the PSA level at which a biopsy should be considered, because, as Dr. Carter put it, \u201cthere\u2019s no level below which we can tell a man he doesn\u2019t have prostate cancer or life-threatening prostate cancer.\u201d\n\nAs one important trial showed, among men with a very low PSA \u2014 that is, a reading below the current cutoff of 4 \u2014 biopsies found that 15 percent had prostate cancer.\nIf more than 25 percent of the PSA is free, chances are that it is being produced by a benignly enlarged prostate.\n", "question": "Does the story commit disease-mongering?", "explanation": "There are several inaccuracies in the description of prostate cancer and prostate cancer screening.\u00a0 One, the story quotes a source who\u00a0attributes the drop in prostate cancer deaths to PSA screening, which is not known for sure (and there were advances in medical treatment at the same time even though this source states there weren't).\u00a0 There could be other reasons for the drop in prostate cancer deaths.\u00a0 Another inaccuracy is that the story states \"guidelines\" (without explaining which guidelines) recommend all men have an annual PSA test beginning at age 50.\u00a0 This is not true; in fact, major guideline-issuing organizations like the American Urological Association, the American Cancer Society, and the U.S. Preventive Services Task Force recommend a shared decision making approach which individualizes this choice based on personal preferences and values.\u00a0 Third, the idea of using PSA velocity in prostate cancer screening has not been well-studied and there is not a lot of evidence to prove the value of this approach.\u00a0 The article states using PSA velocity is a better approach than using a single test for prostate cancer screening, which has not yet been proven (although this approach is often used in monitoring advanced disease after diagnosis).\u00a0 Although a minor inaccuracy, the article also quotes a source who states that PSA does not fluctuate based on sexual activity.\u00a0 However, the evidence for this is mixed and not conclusive.\u00a0 ", "answer": 0}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nDr. Moreira and colleagues write, \"These reported cases include our learning curve patients as we familiarized ourselves with appropriate patient selection and surgical technique.\"\n\"The DTI approach is a powerful tool for breast reconstruction in elderly patients,\" comments ASPS Member Surgeon Andrea Moreira, MD, of the Cleveland Clinic.\nThe authors note some important limitations of their study--particularly the fact that it was a review study of one hospital's experience with a relatively new procedure.\nDr. Moreira adds, \"In appropriately selected cases, DTI reconstruction is a viable alternative to staged techniques requiring multiple surgeries.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release. However, the assumption of the release is that there is something wrong with the fact that most women older than 65 choose not to have breast reconstruction. And the implication is that these women would opt for reconstruction if it were more convenient than the current procedure. Maybe that is the case, but we don\u2019t know why they choose what they choose.\nReconstruction requires being under anesthesia for a long time and there are known risks associated with implants. It also takes a while before the implants feel \u201cnormal.\u201d None of these potential reasons for not having reconstruction surgery over age 65 were addressed in the release. That omission could suggest that women not opting for reconstruction is somehow a problem that needs to be remedied. And that\u2019s concerning if those women are simply making a sensible choice to forego a procedure that lacks medical need but carries higher risks.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story commit disease-mongering?", "explanation": "Basal or squamous cell cancers afflict more Americans annually than all other cancers combined, according to the story. \u00a0While generally not lethal, they require treatment, and that makes these types of cancers indeed a significant problem. What\u2019s key to remember is that this treatment really should only be considered for the face or other areas where standard excisional surgery is not feasible. The other element that the story could have emphasized is that it is recommend only for older individuals, >50.", "answer": 1}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nThe research team is now looking to fund a full clinical trial.\nWith help from industry partners we will be able to further develop the Odoreader, which will enable it to be used where it is needed most; at a patient's bedside, in a doctor's surgery, in a clinic or Walk In Centre, providing fast, inexpensive, accurate results.\"\nAfter further sample testing the next step is to take this technology and put it into a user friendly format.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering, but we were concerned that the release unjustly pushes the \u201curgency\u201d of the need for testing. More on that under the \u201cUnjustifiable language\u201d section below.", "answer": 1}, {"article": "First published on September 5, 2007 at 12:00 am\n\"The exactness of bypass surgery is so high that many people are reluctant to do it without tactile as well as visual feedback.\"\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\nThe maker of the robotic systems, Intuitive Surgical Inc. of Sunnyvale, Calif., is an enthusiastic backer of the University of Chicago's initiative.\nSrivastava said it is true that the normal sense of touch is missing from robotic work, and that is a shortcoming, but it can be overcome with practice.\n", "question": "Does the story commit disease-mongering?", "explanation": "Quoting the marketing director of the company that makes the robotic systems, the story suggests that bypass surgery may be safer than using a stent to keep an artery open, generating fears about the safety of stents. The data about stent risk is complex and in dispute. This implication of greater risk from stenting should not have been reported unless it was investigated further.\u00a0", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story commit disease-mongering?", "explanation": "The story avoids disease-mongering, noting that ocular melanoma is rare.", "answer": 1}, {"article": "Normally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\nThe results, say Gilbert, are important in developing a new form of protection that researchers hope could spell the end of flu vaccination supply problems.\n\"Whether it's this vaccine or another one someone else develops, I don't think we'll be continuing with the type of flu vaccines that we have at the moment.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "- People born without the CCR5 gene are generally healthy, but will deleting it have unforeseen consequences?\nThe sixth man also had modified cells, but fewer than expected.\nThree months later, five men had three times the number of modified cells expected.\nThe only side effect was two days of flulike symptoms.\nThis is the first time researchers have permanently deleted a human gene and infused the altered cells back into patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\n\"But they're not an easy group of patients to transplant.\"\nThe boy is currently on chemotherapy, the study authors noted.\nIn fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.\nThe National Marrow Donor Program has more on Wiskott-Aldrich syndrome.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t exaggerate the consequences of Wiskott-Aldrich syndrome.", "answer": 1}, {"article": "\u201cIt felt as though my head was a cement block,\u201d Kaufman told NBC News.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\nThe aim of the medication is to stop a migraine before it even starts.\nFor 63-year-old Lynn Kaufman, the battle against migraines consumed her life.\nAccording to UCSF Medical Center, more than 35 million Americans suffer from migraine attacks.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story skirts the line here. The dramatic patient anecdote that leads the piece is not a typical presentation for a chronic migraine sufferer.\nHowever, the story redeems itself with a good description of the condition and its prevalence:\n\u2026more than 35 million Americans suffer from migraine attacks. About 4 million sufferers have chronic migraine, with headaches for 10 to 14 days a month. Most migraines are benign, although they can be disabling.", "answer": 1}, {"article": "But don't rush out to adopt a furry friend just yet.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nIt's far too early to predict how this finding will play out in the future, but Kozyrskyj doesn't rule out the concept of a \"dog in a pill\" as a preventive tool for allergies and obesity.\nHer team of 12, including study co-author and U of A post-doctoral fellow Hein Min Tun, take the science one step closer to understanding the connection by identifying that exposure to pets in the womb or up to three months after birth increases the abundance of two bacteria, Ruminococcus and Oscillospira, which have been linked with reduced childhood allergies and obesity, respectively.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no obvious disease mongering here, but the release might plant the suggestion that if readers don\u2019t own a dog and don\u2019t expose their infant to dog-related bacteria, then they may be exposing their children to a greater risk of some form of allergy or even obesity later on. It\u2019s important for releases about association studies like this one was to describe the prevalence of a disease or condition so that people have a sense of what the normal rate of allergies might be in households with or without a dog.", "answer": 0}, {"article": "According to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nDr. Rajat Barua, the paper's corresponding author, says the study is also noteworthy because of its finding that administering the right dose is critical: Treating \"low T\" but not restoring levels to normal doesn't appear to impart much benefit, at least in terms of cardiovascular risk.\nWhile the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\nThe findings may sway the ongoing debate over testosterone therapy's benefits and risks, especially for the heart.\nMore research is needed, they say, to clarify how testosterone affects the cardiovascular system.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We are of two minds on this criterion. The news release leads the reader to infer that low testosterone levels are a health problem, but the existing research in this area offers only mixed support for that.\u00a0 If testosterone levels indeed are causally related to heart attacks and strokes, then this study has identified a substantive health issue.\u00a0 But it is not clear that existing research makes that conclusion possible.\nTo the release\u2019s credit, it does specifically warn that\u00a0doctors should not write a prescription simply because an older man is complaining of symptoms such as low energy and low sex drive. In this sense, it does push back to some extent against drug company promotional efforts surrounding \u201clow T,\u201d which we\u2019ve previously flagged for disease-mongering.", "answer": 1}, {"article": "Almost everyone suffering from back pain says something like, \"I want to feel better, I want to play golf again, or I want to be able to play baseball with my grandkids,\" anesthesiologist and lead author Steve P. Cohen tells Shots.\nThe study's suggestion on how to manage back pain also runs counter to current guidelines from major medical groups.\nDoing away with a painkilling injections, or nerve blocks, as a test to determine the root cause of the back pain didn't hurt patients who went on to have their pain treated by zapping nerves with electrodes.\nPatients don't care much about the finer points of diagnostic accuracy.\nDoctors may not change their approach anytime soon, however.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0No disease-mongering.\u00a0 The story was about pinpointing causes of low back pain \u2013 a condition as broad as the ocean. ", "answer": 1}, {"article": "\u201cA.A.\nDespite the largely negative findings, John F. Kelly, a clinical psychologist at Harvard, said he still believed that A.A. and other 12-step programs were effective.\n\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nThe review covered only carefully controlled trials.\nThe paper was published last week in The Cochrane Library, a journal devoted to systematic reviews of health care interventions.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. The story appropriately provides information from the study and discusses contributing factors of alcohol dependence, including genetics, environmental causes and/or emotional stress. ", "answer": 1}, {"article": "Chemotherapy and other cancer therapies can wreak havoc on the taste buds and olfactory senses, depriving recipients of the intricate interplay between taste and smell that is critical to grasping flavors and enjoying foods.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\nThe team's findings will make it possible for cancer patients to taste foods properly and to enjoy a healthier appetite, enabling more optimal nutrition during a critical period of recovery.\nTheir findings could bring relief to millions of patients undergoing cancer treatment.\nThis research could help us develop TSA-targeted biomarkers and strategies for improving quality of life during chemotherapy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This news release does not disease monger. Rather, it clearly states that TSA in cancer patients is a common problem, and can be detrimental to cancer patients\u2019 recovery.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\nAdditional research is needed to identify which women are more likely to experience severe labor pain and who would benefit the most from effective labor pain-control strategies to help reduce the risk and affect of pain on postpartum recovery.\nAnd, therefore, alleviating this pain might help reduce the risk for postpartum depression.\nIn the study, researchers reviewed the medical records of 201 women who used epidural analgesia and had their pain assessed using a 0-10 scale during labor.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We found the statement that labor pain \u201cmay be psychologically harmful for some women and play a significant role in the development of postpartum depression\u201d a gratuitous assessment, especially given that humans have been bearing children for hundreds of thousands of years without modern analgesics. This statement might scare women away from a perfectly viable alternative, i.e. birth without medicated pain relief.", "answer": 0}, {"article": "Traditionally, patients with leukemia, lymphoma and myeloma have first tried to find an adult bone marrow donor either from a close relative or from a national bone marrow registry.\nBut Tirpak's physician, Dr. Mary Laughlin, turned to something deemed medical waste until recently: umbilical cord blood.\nAnd patients still must endure months of recovery.\nWell worth it, say Mumford and Tirpak, who received her stem cell injection two years ago.\nUntil recently, Tirpak would have faced a death sentence without a bone marrow transplant.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not appear to engage in disease-mongering.", "answer": 1}, {"article": "\u201cThis cost saving can be both to the individual, and if appropriate, to the insurance companies that may provide individuals with assistive devices.\u201d\n\nPartners in research: This work was supported in part by the Vision Health Research Network, the Fonds de recherche du Qu\u00e9b\u00e9c - Sant\u00e9, the Antoine Turmel Foundation, CRIR, and the MAB-Mackay Foundation.\nThe study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\nFor the study, the Concordia-based research team recruited 100 participants who ranged in age from 24 to 97.\nA study recently described in Good Times Magazine provides the first experimental evidence that the Apple iPad is as good as technology traditionally used in reading rehabilitation for individuals with visual impairment.\n\u201cUnsurprisingly, we found that most participants found it hard to read small and medium text, while nearly a quarter of them reported that reading large text was much easier,\u201d says Elliott Morrice, an MA student in Concordia\u2019s Department of Psychology and the study\u2019s first author.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release. It provides an accurate overview of how often age-related vision loss occurs.", "answer": 1}, {"article": "#Nosmokingduringpregnancy.\u201d\n\nAbout the American Journal of Respiratory and Critical Care Medicine\n\nThe AJRCCM is a peer-reviewed journal published by the American Thoracic Society.\nThe authors believe that future trials of vitamin C supplementation in pregnant smokers should determine whether the benefits are greater if the supplementation starts earlier and continues postnatally in the babies themselves.\nThe researchers wrote that study results support the hypothesis that oxidative stress caused by cigarette smoking reduces the amount of ascorbic acid, a component of vitamin C, available to the body.\nSumming up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present \u201ca safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide.\u201d\n\nHowever, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials.\nInfants in this study will continue to be followed to track their lung function and respiratory outcomes.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release doesn\u2019t engage in disease mongering \u2014 there\u2019s a recognized association between smoke exposure and adverse health effects in children. But nor does it give us any idea of the scope of the problem. According to the Centers for Disease Control and Prevention (CDC), about 10% of expectant mothers surveyed said they smoked during the last 3 months of their pregnancy.", "answer": 2}, {"article": "But when it recurs and becomes metastatic, it's very difficult to treat,\" she explained.\nIn the meantime, she pointed out, a woman walking through a clinic door who is diagnosed with triple-negative breast cancer shouldn't panic.\nThe findings were enough to generate the interest of Dr. Lisa A. Carey, the co-author of an accompanying editorial.\nThis was a phase 2 trial.\nIt didn't seem to add any appreciable toxicity to chemotherapy.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nWe\u2019d exhausted the other options in trying to control his cholesterol.\u201d\n\nTwo months after he started his biweekly injections of the new drug, Mr. Brown\u2019s LDL cholesterol level was down to 111 \u2013 not quite normal, which is 100 or less \u2013 but an almost 50 percent reduction from the level it had been for years.\nEven with this trio of medicines, Mr. Brown\u2019s LDL cholesterol level hovered around 200.\nDr. Cohen, Professor of Internal Medicine and with the McDermott Center, holds the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This is a close call but we think it crosses the line to Not Satisfactory. We stated this above, but it bears repeating: High levels of cholesterol, especially high levels of LDL cholesterol relative to high-density lipoprotein cholesterol, are widely considered a significant risk factor for heart disease. However, it is only a risk factor \u2014 it is not a disease in itself. The release refers to \u201cdangerously high levels of cholesterol\u201d in its opening paragraph, and it focuses on the story of a patient with familial hypercholesterolemia \u2014 a condition that is known to cause premature heart disease. But it never tells readers that cholesterol is only a risk factor and doesn\u2019t give any insight into how common this condition is or how worried the average reader should be about it.\u00a0\u201cThere are many more Frank Browns out there \u2013 patients who can\u2019t control their cholesterol with the standard drugs,\u201d the release says. How many?", "answer": 0}]